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Abstract 
Coronaviruses are known to cause disease in humans and animals. Two important human 
coronaviruses that have caused epidemics are severe acute respiratory syndrome coronavirus 
(SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). These 
coronaviruses originated in animals and were introduced into the human population through 
zoonotic transmission.  
Neoromicia capensis coronavirus (NeoCoV), a bat coronavirus that was discovered in the South 
African bat species Neoromicia capensis, is 85.5% genetically identical to MERS-CoV. It is 
believed that NeoCoV is an ancestor of MERS-CoV; however, the potential for NeoCoV to 
emerge as a potential zoonotic agent has not yet been investigated. This study investigated the 
host range of NeoCoV in order to assess its potential to cross the species barrier from bats to 
other mammals.  
This study attempted to isolate NeoCoV in cell culture to investigate its behaviour in vitro. The 
host range of NeoCoV was further explored by developing viral pseudoparticles that expressed 
the spike proteins of NeoCoV, MERS-CoV or SARS-CoV. These pseudoparticles were used to 
infect various cell lines of mammalian origin to determine which animal species NeoCoV may be 
able to infect and if its host range has any similarities to that of MERS- and/or SARS-CoV.  
Attempts were made to isolate NeoCoV in cell culture by inoculating host-derived cells with 
NeoCoV-positive bat faecal homogenate. Attempts were proven unsuccessful by a highly 
sensitive quantitative reverse transcription polymerase chain reaction assay.  
Infecting cell lines with pseudoparticles bearing either the NeoCoV, MERS- or SARS-CoV spike 
protein revealed that NeoCoV could possibly utilise N. capensis kidney cells for replication, and 
not the lungs or trachea. Infection of Pipistrellus pipistrellus kidney cells with the three different 
pseudotypes yielded low levels of infection, suggesting that this cell line is less susceptible to 
infection by the three viruses. None of the pseudotypes generated were able to infect a kidney 
cell line derived from Camelus dromedarius, a known host of MERS-CoV, indicating that camel 
kidney cells are likely not the site of MERS-CoV replication. Results from pseudoparticle 
infection experiments suggest that NeoCoV would have the ability to infect Vero cells, which 
originate from African green monkey kidneys, with the same efficiency as MERS- and SARS-
CoV.  
Since pseudoparticles bearing the spike protein of NeoCoV have the ability to infect Vero cells, 
NeoCoV might have the ability to cross the species barrier from its natural host to non-human 
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primates such as Cercopithecus aethiops. As the human population encroaches on wildlife 
habitats, the transmission of viruses capable of crossing the species barrier becomes an 
increasing risk to public health.  
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Opsomming 
Coronavirusse veroorsaak siektes in mense en diere. Twee prominente menslike coronavirusse, 
erge akute respiratoriese sindroomcoronavirus (SARS-CoV) en Midde-Ooste respiratoriese 
sindroomcoronavirus (MERS-CoV), het epidemies in mense veroorsaak. Hierdie virusse is van 
diergashere afkomstig en het die menslike bevolking deur zoönotiese oordrag binnegedring.  
Neoromicia capensis-coronavirus (NeoCoV), „n vlermuiscoronavirus wat in die Suid-Afrikaanse 
vlermuisspesie Neoromicia capensis ontdek is, is 85.5% geneties identies aan MERS-CoV. Daar 
word vermoed dat NeoCoV „n voorouer van MERS-CoV is; NeoCoV se potensiaal om as 
zoönotiese agent op te tree, is egter nog nie ondersoek nie. Hierdie studie het die 
gasheeromvang van NeoCoV ondersoek in „n poging om die virus se potensiaal om die grens 
van vlermuise na ander soogdiere oor te steek, te evalueer.  
Die studie het gepoog om NeoCoV in selkultuur te isoleer om die gedrag van die virus in vitro te 
bestudeer. Die gasheeromvang van NeoCoV is verder ondersoek deur virale pseudopartikels 
wat die uitsteekselproteïene van NeoCoV, MERS-CoV of SARS-CoV op hul oppervlak uitdruk, te 
ontwikkel. Hierdie pseudopartikels is gebruik om verskeie sellyne van soogdieroorsprong te 
infekteer om vas te stel of NeoCoV oor die vermoë om hierdie selle binne te gaan, beskik, en of 
die virus se gasheeromvang enige ooreenkomste met dié van MERS- en/of SARS-CoV toon.  
Daar is gepoog om NeoCoV in selkultuur te isoleer deur selle afkomstig van die gasheer met 
NeoCoV-positiewe vlermuisontlastingshomogenaat te inokuleer. Pogings is deur „n hoogs 
sensitiewe kwantitatiewe trutranskripsie-polimerasekettingreaksie-toets onsuksesvol bewys. 
Die infektering van sellyne met pseudopartikels wat die NeoCoV-, MERS-CoV of SARS-CoV-
uitsteekselproteïen uitdruk, het geopenbaar dat NeoCoV moontlik N. capensis-nierselle, en nie 
die longe of trachea nie, vir replisering gebruik. Infektering van Pipistrellus pipistrellus-nierselle 
met die drie pseudotipes het lae vlakke van infeksie gelewer, wat suggereer dat die sellyn 
minder vatbaar vir infeksie deur die drie virusse is. Geeneen van die gegenereerde pseudotipes 
kon „n sellyn wat afkomstig is van Camelus dromedarius, „n bevestigde MERS-CoV-gasheer, 
infekteer nie, wat aandui dat kameelnierselle waarskynlik nie die repliseringsetel van MERS-CoV 
is nie. Pseudopartikelinfekteringsresultate dui daarop dat NeoCoV die vermoë het om Vero-
selle, wat van Afrikaanse groenaapnier afkomstig is, met dieselfde doeltreffendheid as MERS- 
en SARS-CoV te infekteer.  
Aangesien pseudopartikels wat die uitsteekselproteïene van NeoCoV uitdruk die vermoë het om 
Vero-selle te infekteer, mag NeoCoV moontlik oor die vermoë om die spesiegrens van sy 
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natuurlike gasheer na nie-menslike primate soos Cercopithecus aethiops oor te steek, beskik. 
Soos die menslike bevolking inbreuk maak op diere se habitat, word die oordrag van virusse wat 
die spesiegrens kan oorsteek „n groter risiko vir openbare gesondheid.  
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CHAPTER 1 
1  Introduction 
1.1  Background 
1.1.1  Coronaviruses 
1.1.1.1  Coronaviruses in humans and animals 
Coronaviruses have been known to infect humans and other mammals on a large scale 
(Masters, 2006; Banerjee et al., 2018). Various epidemics caused by coronaviruses, such as 
that of Middle East respiratory syndrome coronavirus (MERS-CoV) (Zaki et al., 2012) and 
severe acute respiratory syndrome coronavirus (SARS-CoV) (Drosten et al., 2003), have been 
observed over the years. Both of these virus outbreaks have been linked to zoonotic 
transmission events, i.e. events where diseases are transmitted from animal hosts to humans.  
Neoromicia capensis coronavirus (NeoCoV) was discovered in the Cape serotine bat, 
Neoromicia capensis, in South Africa in 2013 (Ithete et al., 2013; Corman et al., 2014). 
Phylogenetic analysis of the viral genome revealed that it is 85.5% identical to MERS-CoV. 
MERS-CoV-related viruses have since been detected in other samples from the same bat 
species (Cronjé, 2017). The relatedness of these viruses leads to the assumption that NeoCoV 
might be an ancestral virus of MERS-CoV (Corman et al., 2014).  
1.1.1.2  Coronavirus spike protein 
The coronavirus genome encodes four major proteins, namely the spike (S), envelope (E), 
membrane (M) and nucleocapsid (N) proteins (Masters, 2006). The S protein is responsible for 
the binding to, and fusion with, host cells (Masters, 2006). The S protein consists of subunits 1 
(S1) and 2 (S2) (Masters, 2006). S1 contains the receptor binding domain (RBD) and is 
responsible for the binding of the viral particle to host cell receptors, whereas S2 enables the 
fusion of viral particles with the host cell. As this protein is responsible for viral entry into host 
cells, its structure is of significance when describing the host range of coronaviruses.  
1.1.2  Pseudoparticles 
Pseudoparticles are replication-deficient viral particles that bear the surface antigen(s) of other 
viruses (Tani et al., 2012). Pseudoparticles are used in instances where it is not possible to 
study the surface antigen of interest when expressed by the virus of origin due to safety 
concerns and/or difficulties with isolating or propagating the virus itself in order to investigate its 
behaviour in cell culture further (Tani et al., 2012).  
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1.1.3  Rationale 
The NeoCoV genome shares 85.5% homology with that of MERS-CoV (Ithete et al., 2013; 
Corman et al., 2014). Since the host-switching abilities of NeoCoV remain unknown, similarities 
between the host ranges of NeoCoV and MERS-CoV have not yet been explored. Therefore, 
strategies to determine which cell lines are susceptible to NeoCoV need to be developed.  
The ability of a virus to infect a cell is highly dependent on its receptor (de Haan & Rottier, 2005; 
Masters, 2006; Hoffmann et al., 2013). The receptor for MERS-CoV was identified as dipeptidyl 
peptidase 4 (DPP4) (Raj et al., 2013), an enzyme involved in the metabolism of glucose (Vlieger 
& De Meester, 2018). This receptor is expressed by many cell lines, such as Vero cells (Zaki et 
al., 2012; Raj et al., 2014), P. pipistrellus kidney cells (Cui et al., 2013; Raj et al., 2014), and C. 
dromedarius umbilical cord cells (Eckerle et al., 2014). The NeoCoV S1 protein is only 45% 
identical to that of MERS-CoV, but their S2 proteins bear a similarity of 87% on the amino acid 
level (Corman et al., 2014). These similarities led to the hypothesis that the viruses should be 
able to infect cell lines originating from the same species and could possibly utilise the same 
receptor.  
Angiotensin-converting enzyme 2 (ACE2) was identified as the receptor for SARS-CoV (Li et al., 
2003), which is expressed in cells originating from human kidneys (Warner et al., 2005; Eckerle 
et al., 2013), human hearts (Boehm & Nabel, 2002; Warner et al., 2005) and African green 
monkey kidneys (Wang et al., 2004).This enzyme is associated with blood pressure regulation 
(Danilczyk et al., 2004). With S1 and S2 of NeoCoV and the more distantly related SARS-CoV 
sharing 20% and 42% similarity on the amino acid level, respectively, it is unlikely that these two 
viruses utilise the same receptor. However, determining whether NeoCoV and SARS-CoV are 
able to infect the same cell lines would provide a greater comprehension of the infectivity of 
NeoCoV.  
If NeoCoV had the ability to infect cell lines susceptible to MERS-CoV and/or SARS-CoV, there 
might be a possibility that NeoCoV might utilise the animal species from which the cell lines 
originate as intermediate hosts in the process of emergence. Knowledge of the host range of 
NeoCoV can be used to determine which other mammalian species NeoCoV could infect, where 
it may have the opportunity to adapt or recombine and possibly emerge as an agent able to 
infect humans.  
Isolation of NeoCoV in cell culture would provide a basis on which to study the characteristics of 
this virus in vitro. Furthermore, isolation of NeoCoV would aid in determining which receptors are 
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utilised by the virus, advancing the current knowledge on which cells would be susceptible to 
infection by NeoCoV. Access to NeoCoV-positive bat faecal samples and host-derived cell lines 
provide advantageous conditions for the establishment of an isolation protocol for NeoCoV.  
Since isolating bat coronaviruses in cell culture remains a major challenge (Banerjee et al., 
2018), a need exists to find an approach that does not involve the use of isolated NeoCoV to 
test the ability of the virus to infect different cell lines. Another problem to be expected when 
working with the virus itself is that different cell lines might require the use of different infection 
protocols. The process of developing cell line-specific isolation protocols can be time-consuming 
and expensive. Furthermore, there is a biological risk involved in working with MERS-CoV and 
SARS-CoV directly (World Health Organization, 2003; Lim et al., 2004; Tani et al., 2012).  
To circumvent the aforementioned challenges, the use of viral pseudoparticles bearing the 
surface antigens of viruses of interest has been proposed. Using viral pseudoparticles ensure 
that approximately equal titres of virus can be generated in order to standardise infection of cell 
lines. Additionally, pseudoparticles express reporter genes that simpliy the detection of infection, 
making the use of expensive and time-consuming procedures such as viral detection by reverse 
transcription (RT) polymerase chain reaction (PCR) (RT-PCR) or quantitative RT-PCR (RT-
qPCR) unnecessary. Viral pseudoparticles could be used to infect different cell lines to test their 
susceptibility to MERS-CoV, NeoCoV and SARS-CoV, with reporter proteins present in the 
particles providing a simple method of detecting infection.  
1.1.4  Strategy for studying viral entry in vitro 
Developing a protocol for the isolation of NeoCoV would be an ideal method to study its viral 
behaviour in vitro. Once NeoCoV has successfully been cultured on an appropriate cell line, the 
protocol can be used to propagate virus to be tested on other cell lines.  
Another approach to study viral entry was the use of viruses that mimic the binding and entry of 
NeoCoV and two human coronaviruses, SARS-CoV and MERS-CoV, in different types of cell 
cultures, and to compare cell susceptibility among the three viruses. To achieve this, a range of 
pseudotyped viruses was developed.  
A recombinant vesicular stomatitis virus (VSV) with the gene of its own envelope glycoprotein 
(VSV-G) removed, developed by Hoffmann et al. (2013), was used to express the envelope 
genes of heterologous viruses. A replication-deficient VSV lacking the VSV-G gene, hereafter 
referred to as VSV*ΔG-Luc, has been made available to our laboratory by collaborators at the 
Charité University Hospital (Berlin, Germany). This system contains genes for the expression of 
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green fluorescent protein (GFP) and firefly luciferase (Luc). The VSV*ΔG-Luc system is only 
able to initiate cell entry but cannot replicate and cause infection and is able to report successful 
infection of cell lines by expression of GFP.  
In order to produce pseudoparticles bearing proteins of interest using this system, baby hamster 
kidney (BHK) cells, strain BHK-21 (G43), were transfected with plasmids containing the genes 
for the MERS-CoV-, NeoCoV- or SARS-CoV S proteins, resulting in expression of the respective 
S proteins on the cell surfaces. The VSV*ΔG-Luc stock was then used to infect these S-
expressing cells, resulting in the budding of pseudoparticles carrying the respective coronavirus 
S proteins. The resulting pseudoparticles were tested on different cell lines to determine which 
cells are susceptible to infection by the aforementioned viruses.  
1.1.5  Aims and objectives 
This study aimed to investigate the host range of NeoCoV in vitro. Establishing a protocol for the 
isolation of NeoCoV in cell culture and producing pseudoparticles were extensions of this aim.  
The objectives for this study were: 
 To culture NeoCoV in cell culture using a cell line derived from its host, N. capensis.  
 To propagate and rescue replication-deficient viral pseudoparticles bearing the S proteins of 
MERS-CoV, NeoCoV or SARS-CoV.  
 To transfect BHK-21 (G43) cells with pCG1 vectors carrying the S protein inserts of 
MERS-CoV, NeoCoV and SARS-CoV.  
 To generate pseudoparticles bearing the S proteins of MERS-CoV, NeoCoV and 
SARS-CoV.  
 To infect mammalian cell lines derived from Camelus dromedarius, N. capensis, 
Pipistrellus pipistrellus and Cercopithecus aethiops with the generated pseudotyped 
viruses to investigate the range of cells susceptible to infection with NeoCoV.   
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1.2  Literature review 
1.2.1  Coronaviruses 
Coronaviruses belong to the family Coronaviridae, which belong to the order Nidovirales (Navas-
Martín & Weiss, 2004; Masters, 2006). Even though this family of viruses is morphologically 
distinguishable from other viruses of the order Nidovirales, sequencing is required to distinguish 
between different viruses from the Coronaviridae family itself (Masters, 2006).  
1.2.1.1  Molecular biology 
Viruses of the family Coronaviridae are enveloped and have single-stranded, positive-sense 
ribonucleic acid (RNA) genomes. These genomes are approximately 30 000 bases in size; the 
largest known RNA genomes in existence (Navas-Martín & Weiss, 2004; Masters, 2006).  
The open reading frame (ORF) 1a and ORF1b are found at the 5‟-end of the genome and make 
up roughly two-thirds of the entire genome as seen in Figure 1.1. These proteins are post-
translationally cleaved into the viral protease and non-structural proteins involved in replication 
(Lai et al., 1994). The last third of the genome that is located at the 3‟-end is transcribed into 
structural proteins (Lai et al., 1994). These structural proteins include the S, E, M and N proteins 
(Navas-Martín & Weiss, 2004; Masters, 2006).  
 
Figure 1.1. A diagram of a typical coronavirus genome. This illustrates the first two-thirds of the 
genome encoding for the replicase genes and the last third of the genome encoding for the structural 
proteins spike (S), envelope (E), membrane (M) and nucleocapsid (N) (Smith & Denison, 2012) 
(permission number for use of image: 4410691200986).  
The S proteins are located on the envelope of coronaviruses. They are club-shaped proteins 
that protrude from the virion‟s surface. These proteins attach to host cells to facilitate fusion of 
virions with host cells (Masters, 2006). The E protein forms part of the virion membrane 
(Masters, 2006). According to Fischer and Sansom (2002), this protein aids in the formation of 
ion channels in the membrane to regulate the virion pH, which, when lowered, enables the viral 
genome to move from the virion to the nucleus of the host cell. The E protein also facilitates 
virion budding in some members of the coronavirus family, such as mouse hepatitis virus (MHV) 
and infectious bronchitis virus (IBV) (Raamsman et al., 2000; Machamer & Youn, 2006). The M 
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protein of coronaviruses is a glycoprotein. It is integrated into the lipid bilayer that forms the viral 
membrane. This protein is responsible for the spherical shape of the virions and offers structural 
support and stability (Masters, 2006). The N proteins of coronaviruses are wound around the 
viral genome to compact it and are helically symmetrical (Kennedy & Johnson-Lussenburg, 
1975). This is not a common feature in positive-sense RNA viruses, which usually have 
icosahedral nucleocapsids (Kennedy & Johnson-Lussenburg, 1975; Masters, 2006).  
1.2.1.2  Replication cycle 
Coronavirus S proteins bind to receptors on the surfaces of host cells at the start of their life 
cycle (de Haan & Rottier, 2005). The coronavirus S protein consists of two subunits: S1 and S2 
(de Haan & Rottier, 2005; Masters, 2006; Cavanagh et al., 2007; Hoffmann et al., 2013). S1 
mediates the binding of the viral particle to receptors on the host cell surface. S2 is responsible 
for the fusion of the virion with the host cell. Seeing as the compatibility of the S protein with the 
receptors on the host cell surface is essential for viral entry, the genetic composition and three-
dimensional structure of the coronaviral S protein plays a significant role in the tropism of 
coronaviruses (de Haan & Rottier, 2005; Masters, 2006; Hoffmann et al., 2013).  
The coronavirus envelope disintegrates once the viral particle binds to the host cell surface and 
the RNA is released into the host cell‟s cytoplasm (de Haan & Rottier, 2005; Masters, 2006). The 
replicase genes are translated to form a replication-transcription complex that aids in the 
replication of the viral genome and translation of the structural proteins S, E, M and N. Proteins 
S, E, M and N attach to the endoplasmic reticulum and Golgi complex to initiate virion assembly, 
after which the virions are exocytosed to become mature virions (La Monica et al., 1992; Navas-
Martín & Weiss, 2004; de Haan & Rottier, 2005; Masters, 2006).  
During the replication process, which is depicted in Figure 1.2, a negative-sense RNA 
intermediate is formed to act as template. The positive-sense genome itself acts as messenger 
RNA (mRNA) for the translation of structural and accessory proteins (La Monica et al., 1992; 
Navas-Martín & Weiss, 2004; de Haan & Rottier, 2005; Masters, 2006; Corman et al., 2014; 
Corman et al., 2015). The polycistronic genome, in which one strand of mRNA encodes more 
than one protein, provides a platform for the genes to be translated and/or replicated 
simultaneously but separately.  
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Figure 1.2. The replication cycle of a coronavirus. The virion binds to receptors on the host cell 
surface, enters the cell and disassembles. The viral genome replicates and structural proteins are 
translated. Thereafter, particles are assembled and exocytosed (de Haan & Rottier, 2005) (permission 
number for use of image: 4410690675754).  
1.2.1.3  Human and animal coronaviruses 
Different coronavirus species have been known to infect humans, other mammals and avian 
species (de Haan & Rottier, 2005; Masters, 2006; Banerjee et al., 2018) and typically infect the 
respiratory and digestive systems (de Haan & Rottier, 2005; Masters, 2006). Coronavirus 
infections can be of an acute or chronic nature, resulting in symptoms such as coughs, a sore 
throat, chills, fever, and other flu-like symptoms (Masters, 2006).  
1.2.1.3.1  Non-zoonotic animal coronaviruses 
Mammals are often found to harbour coronaviruses that are not transmissible to humans. Some 
of these non-zoonotic animal coronaviruses include transmissible gastroenteritis coronavirus 
(TGEV), bovine coronavirus (BCoV), feline coronavirus, turkey coronavirus (TCV), ferret enteric 
coronavirus and pantropic canine coronavirus.  
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TGEV is a pathogen of pigs. It was first described by Doyle and Hutchings (1946). TGEV causes 
diarrhoea in pigs and is often fatal for piglets.  
BCoV is found in cattle and other ruminants such as Sambar deer (Cervus unicolor) and 
waterbuck (Kobus ellipsiprymnus) (Saif & Heckert, 1990; Tsunemitsu et al., 1995). BCoV causes 
respiratory and enteric infections in ruminants (Saif & Heckert, 1990; Tsunemitsu et al., 1995).  
Feline coronavirus exists as two pathotypes, namely feline enteric coronavirus (FECV) and feline 
infectious peritonitis virus (FIPV) (Rottier et al., 2005). FECV and FIPV manifests as two different 
diseases in felines (Rottier et al., 2005). Both of these manifestations cause infection of 
epithelial cells in the gastrointestinal tract, from where it can spread through viraemia 
(Herrewegh et al., 1995; Sharif et al., 2011; Desmarets et al., 2016).  
TCV causes inflammation of the intestinal tract of turkeys (Adams & Hofstad, 1971). This results 
in inflammation of the intestines, with symptoms such as diarrhoea and dehydration. TCV often 
has a high fatality rate, especially in young individuals.  
Ferret enteric coronavirus is the causative agent of a disease that spreads between young 
ferrets and is frequently transmitted from young individuals to adults (Williams et al., 2000; Wise 
et al., 2006). The virus causes inflammation of the mucous membranes of ferrets. The disease 
results in dehydration, usually caused by vomiting and diarrhoea.  
Pantropic canine coronavirus, described by Erles et al. (2003), causes canine infectious 
respiratory disease. As the name implies, many different tissue types are susceptible to infection 
by pantropic canine coronavirus. The virus can also manifest as a neurologic condition, resulting 
in lowered coordination and, in more severe cases, seizures.  
1.2.1.3.2  Coronavirus diseases in humans 
Human coronaviruses are transmitted in various ways, among others through microdroplet 
transmission, fomites and faecal-oral routes (Graham et al., 2013; Raj et al., 2014; Baseler et al., 
2016; Scully & Samaranayake, 2016).  
Mild coronavirus infection in humans can include symptoms such as fever, chills, muscular pain, 
shortness of breath, coughs, sore throat and runny nose, general feeling of physical discomfort 
caused by immunosuppression, and other common cold-like symptoms (Graham et al., 2013; 
Raj et al., 2014; Baseler et al., 2016; Scully & Samaranayake, 2016). In severe infections, renal 
failure and pneumonia have been reported (Baseler et al., 2016). In some cases, patients have 
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been asymptomatic despite being infected with a coronavirus (Raj et al., 2014; Baseler et al., 
2016).  
There are currently six coronaviruses known to cause disease in humans (Centers for Disease 
Control and Prevention, 2017). These viruses are human coronaviruses (HCoV) 229E, HCoV-
OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV (Centers for Disease Control and 
Prevention, 2017).  
HCoV-229E was originally isolated by Hamre and Procknow (1966). The virus belongs to the 
alphacoronavirus genus and causes infection in the upper respiratory tract (Hamre & Procknow, 
1966; Vabret et al., 2003). It is one of the causative agents of the common cold, but can also 
result in more severe diseases such as pneumonia (Vabret et al., 2003). HCoV-229E is believed 
to be of bat origin (Graham et al., 2013).  
HCoV-OC43, originally described by McIntosh et al. (1967), is a betacoronavirus that causes 
upper respiratory tract infections (Vabret et al., 2003). The virus is also associated with the 
manifestation of the common cold and can lead to the development of pneumonia or bronchitis 
in more severe cases (Vabret et al., 2003).  
Van der Hoek et al. (2004) identified HCoV-NL63 as the causative agent of bronchiolitis in an 
infant; thus discovering the fourth disease-causing HCoV. This virus belongs to the genus 
alphacoronaviruses and causes respiratory tract infections in humans, leading to mild infections. 
It can also result in diseases such as pneumonia and bronchiolitis, especially in 
immunocompromised individuals (van der Hoek et al., 2004; Chiu et al., 2005). According to 
Graham et al. (2013), HCoV-NL63 also originates from bats.  
HCoV-HKU1 was first described by Woo et al. (2005). It is a betacoronavirus that causes 
infection of the respiratory tract. HCoV-HKU1-infection can result in diseases such as the 
common cold, pneumonia and bronchitis (Kanwar et al., 2017).  
SARS-CoV (Drosten et al., 2003) and MERS-CoV (Zaki et al., 2012) are two of the most 
pathogenic human coronaviruses discovered to date. Both of these viruses have been found to 
originate from animal hosts (Guan et al., 2003; Lau et al., 2005; Li et al., 2005, Yuan et al., 2010; 
Perera et al., 2013; Reusken et al., 2013; Haagmans et al., 2014; Nowotny & Kolodziejek, 2014; 
Yang et al., 2016) and are described in more detail in subsequent sections (refer to sections 
1.2.1.3.4 and 1.2.1.3.5).  
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1.2.1.3.3  Zoonotic transmission of coronaviruses from animals to humans 
Zoonosis is the term used to describe a disease that can be transmitted from animals to humans 
(The Oxford English Dictionary, 2018). Viral zoonoses and the emergence of novel infectious 
viruses are often associated with RNA viruses due to their high mutation rates that cause 
variants to develop that can „jump‟ from one host species to another (Scully & Samaranayake, 
2016). Host-switching can also facilitate faster spread of diseases as the infections can spread 
between humans and animals and in the human population itself once it has adapted to its new 
host system (Otter et al., 2016).  
Some coronavirus outbreaks in the human population have resulted in the discovery of related 
viruses in other mammals, such as the discovery of MERS-CoV-like viruses in bats (Annan et 
al., 2013; Ithete et al., 2013; Corman et al., 2014; Lau et al., 2018a) and MERS-CoV itself in 
camels (Perera et al., 2013; Reusken et al., 2013; Haagmans et al., 2014). SARS-CoV-like 
viruses have also been found in bats (Lau et al., 2005; Li et al., 2005, Yuan et al., 2010) and 
civets (Guan et al., 2003; Lau et al., 2005). Phylogenetic analysis of the genomes of these 
viruses has shown close relatedness between human and animal-derived coronavirus 
sequences and has led to the notion that some coronavirus outbreaks are the result of zoonotic 
transmission events (Guan et al., 2003; Lau et al., 2005; Li et al., 2005; Yuan et al., 2010; Annan 
et al., 2013; Ithete et al., 2013; Perera et al., 2013; Reusken et al., 2013; Corman et al., 2014; 
Haagmans et al., 2014; Lau et al., 2018a).  
The host range of coronaviruses is largely determined by their surface proteins‟ ability to bind to 
host cell surface receptors. Coronavirus S proteins consist of two subunits, S1 and S2. These 
subunits play an important role in host-switching, seeing as the ability of the virus to adapt its S 
protein subunits to bind to different receptors determine whether it can „jump‟ from one host to 
another (Hoffmann et al., 2013).  
There is a variety of coronaviruses that can infect vertebrates. These viruses can cause 
diseases that affect the respiratory, gastrointestinal and central nervous systems (Shi et al., 
2016). Coronaviruses have been proven to infect various hosts, such as civets, camels and bats 
(Masters, 2006; Smith & Denison, 2012; Coleman & Frieman, 2014; Corman et al., 2014, 
Moratelli & Calisher, 2015, Banerjee et al., 2018). There is evidence that suggests transmission 
of coronavirus from animals to humans occurs (Guan et al., 2003; Reusken et al., 2013; 
Nowotny & Kolodziejek, 2014). This is a public health risk in instances where humans are in 
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close contact with animals, as is the case with domesticated and farm animals (Coleman & 
Frieman, 2014).  
Bats are known to host a wide variety of viruses and they are suspected to host viruses that can 
adapt to infect human populations, either directly or through intermediate hosts (Calisher et al., 
2006). Human viruses that originated from bats include rabies virus (Dato et al., 2016), 
henipavirus (Pernet et al., 2014), Menangle virus (Barr et al., 2012) and Ebola virus (Leroy et al., 
2009). Some bat species, such as Hipposideros caffer ruber of Ghanaian origin (Pfefferle et al., 
2009) and several North American bat species (Huynh et al., 2012), have been found to host 
coronaviruses that are related to known human coronaviruses, indicating that bats might have 
played a role in the emergence of these viruses in humans. This is cause for concern, since 
some bats nest close to human populations and can travel great distances, thus having the 
means to spread viruses widely through zoonotic transmission. Once a human has been 
infected and the virus has adapted to facilitate human transmission, the virus can be spread 
rapidly in the human population, leading to an outbreak.  
1.2.1.3.4  Severe acute respiratory syndrome coronavirus 
A coronavirus named SARS-CoV caused an outbreak of severe respiratory disease in China in 
2003 (Drosten et al., 2003; World Health Organization, 2003). The disease spread to 37 
countries and resulted in 8 273 cases and 775 deaths (Drosten et al., 2003; Navas-Martín & 
Weiss, 2004; Graham et al., 2013; Coleman & Frieman, 2014; Corman et al., 2014). SARS-CoV 
was predominantly spread through droplet transmission, but was also linked to transmission 
through fomites (Otter et al., 2016). Some patients with SARS-CoV infections showed symptoms 
such as fever, migraines, cough, and general discomfort, whilst more serious infections caused 
symptoms ranging from pneumonia and respiratory failure to liver or heart failure (Berger et al., 
2004; Navas-Martín & Weiss, 2004).  
The receptor for SARS-CoV was identified by Li et al. (2003) as ACE2. This receptor is found on 
numerous cell types, including those from human kidneys (Warner et al., 2005; Eckerle et al., 
2013), human hearts (Boehm & Nabel, 2002; Warner et al., 2005), African green monkey 
kidneys (Wang et al., 2004), Madin-Darby canine kidney (MDCK) cells (Warner et al., 2005), 
Chinese hamster (Cricetulus griseus) ovaries (CHO) (Warner et al., 2005), human colons, 
human embryonic kidney (HEK) cells, human endometrial adenocarcinoma cells, human 
alveolar adenocarcinoma cells, human cervical cancer cells, and feline (Felis catus) lungs 
(Mossel et al., 2005). This suggests that all the aforementioned cell lines may be susceptible to 
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infection with SARS-CoV; however, it has not been possible for researchers to successfully 
infect all of these cells with SARS-CoV in cell culture (Mossel et al., 2005).  
One of the first SARS-CoV patients is believed to have contracted the disease from civets 
(Paguma larvata) and raccoon dogs (Nyctereutes procyonoides) through zoonotic transmission. 
Horseshoe bats (Rhinolophus sinicus) have also been found to carry antibodies against SARS-
CoV and indicate yet another zoonotic source of this disease (Breiman et al., 2003; Graham et 
al., 2013; Coleman & Frieman, 2014). Furthermore, a SARS-CoV progenitor more closely 
related to the virus than any other discovered in animal hosts before was discovered in Chinese 
horseshoe bats (Yang et al., 2016). It is speculated that the virus „jumped‟ from horseshoe bats 
to civets and raccoon dogs and from there to humans, likely undergoing genetic adaption with 
each host-switch (Graham et al., 2013). The virus might have been transmitted from the bats to 
the civets through a faecal-oral route when nesting close together, which could then have been 
transmitted to humans when they handled the civets or ate undercooked civet meat (Graham et 
al., 2013).  
1.2.1.3.5  Middle East respiratory syndrome coronavirus 
An outbreak of MERS-CoV originated in the Arabian Peninsula in 2012 and is still on-going (Zaki 
et al., 2012; World Health Organization, 2018). To date, the virus has spread to 27 countries and 
has resulted in 2 260 cases and 803 deaths (World Health Organization, 2018). MERS-CoV 
infects the lower respiratory tract of humans (Scully & Samaranayake, 2016). Infected 
individuals usually present with symptoms such as fever, chills, migraines, coughs, sore throats, 
muscular pain, nausea, and chest pain when breathing. More severe symptoms include 
pneumonia and renal failure (Baseler et al., 2016).  
Raj et al. (2013) identified DPP4 as the functional receptor for MERS-CoV. A myriad of cells 
express this receptor, among others African green monkey kidney cells (Zaki et al., 2012; Raj et 
al., 2014), human liver cells (Raj et al., 2014), P. pipistrellus kidney cells (Cui et al., 2013; Raj et 
al., 2014), human bronchial and lung tissue cells (Chan et al., 2013) equine (Equus caballus) 
kidney cells (Meyer et al., 2015), ferret (Mustela putorius furo) kidney cells (Raj et al., 2014), 
rhesus macaque (Macaca mulatta) kidney cells, human lung adenocarcinoma cells, human 
epithelial colorectal adenocarcinoma cells and HEK cells (Shirato et al., 2013). Furthermore, 
goat (Capra hircus) lung cells, alpaca (Llama pacos) kidney cells, dromedary camel (C. 
dromedarius) umbilical cord cells, sheep (Ovis aries) kidney cells, cattle (Bos taurus) kidney and 
lung cells, bank vole (Myodes glareolus) trachea cells and lesser white-toothed shrew (Crocidura 
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suaveolens) lung cells also express DPP4 (Eckerle et al., 2014). Although many of these cells 
have been inoculated with MERS-CoV in vitro, not all of these cells have shown susceptibility to 
the virus in cell culture.  
Some evidence suggests that bats have transmitted ancestral variants of MERS-CoV to 
dromedary camels through an intermediate host(s) (Coleman & Frieman, 2014; Corman et al., 
2014). MERS-CoV has been found in many populations of dromedary camels and thus 
implicates these animals as a reservoir host for the virus (Reusken et al., 2013; Coleman & 
Frieman, 2014; Corman et al., 2014; van den Brand et al., 2015). The „jump‟ from camels to an 
intermediate host or directly to humans likely required some genetic changes to adapt for human 
infection and transmission (de Wit & Munster, 2013; Reusken et al., 2016). Humans were 
possibly initially infected with the virus when working with camels (Coleman & Frieman, 2014; 
Corman et al., 2014; Raj et al., 2014; Baseler et al., 2016).  
Some bat species have been shown to carry coronaviruses that are closely related to MERS-
CoV (de Groot et al., 2013; Ithete et al., 2013; Memish et al., 2013; Corman et al., 2014; Banik 
et al., 2015; Anthony et al., 2017; Cronjé, 2017; Moreno et al., 2017; Lau et al., 2018b). Upon 
the discovery of MERS-CoV, it was found that MERS-CoV was related to two bat coronaviruses, 
namely Tylonycteris bat coronavirus HKU4 (Ty-BatCoV HKU4) and Pipistrellus bat coronavirus 
HKU5 (Pi-BatCoV HKU5) (Wang et al., 2014; Yang et al., 2014), which were discovered in 
China. This indicated that bats might harbour the ancestral viruses from which MERS-CoV 
developed by means of mutations and other genomic modifications in other reservoir hosts 
(Wang et al., 2014; Yang et al., 2014; Lau et al., 2018a).  
Several studies have detected MERS-related coronaviruses in African bats (Corman et al., 2014; 
Anthony et al., 2017; Cronjé, 2017). Anthony et al. (2017) discovered a coronavirus, 
PREDICT/PDF-2180, in the bat species Pipistrellus hesperidus that is related to MERS-CoV in 
Uganda. The S protein of PREDICT/PDF-2180 was genetically distinct from that of MERS-CoV, 
with which it shared only 46% homology on the amino acid level (Anthony et al., 2017). It was 
discovered that this disparity between the S proteins makes it impossible for PREDICT/PDF-
2180 to bind to human DPP4. This was confirmed by protein modelling (refer to section 1.2.1.4), 
during which the S protein structure of PREDICT/PDF-2180 was predicted and visualised in 
silico with specialised software to determine whether it shared similarities with the MERS-CoV S 
protein on a phenotypic level (Anthony et al., 2017). Furthermore, the study constructed full-
length infectious clones of the MERS-CoV genome, replacing the RBD of MERS-CoV with that 
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of PREDICT/PDF-2180 and transfecting cells with these clones. Cells produced recombinant 
viruses which were harvested and used to infect Vero cells, but no replicating virus could be 
detected through RT-PCR, leading to the conclusion that PREDICT/PDR-2180 does not have 
the ability to utilise human DPP4 (Anthony et al., 2017). This virus is therefore not believed to 
pose a zoonotic threat (Anthony et al., 2017).  
Human MERS-CoV itself has not been found in bats; however, the RBD of a closely related bat 
coronavirus, namely HKU4, can bind human DPP4, albeit with a lower affinity than that of 
MERS-CoV (Wang et al., 2014). More recently, Lau et al. (2018b) discovered the RBD of 
another bat coronavirus strain, Hp-BatCoV HKU25, originating from Hypsugo pulveratus, can 
bind to human DPP4 for viral entry by replacing the MERS-CoV RBD with that of the novel 
strain. Lau et al. (2018b) also developed pseudoparticles bearing the S protein of Hp-BatCoV 
HKU25 to confirm that the virus is able to utilise human DPP4. The pseudoparticles were able to 
enter human cells, but with a lower efficiency than MERS-CoV. Taking this into account, it is 
speculated that MERS-CoV reached the human population after a series of genetic changes that 
was possibly brought about by multiple host-switching and recombination events, during which 
the S protein adapted to enter human cells (de Wit & Munster, 2013; Corman et al., 2014; Banik 
et al., 2015; van den Brand et al., 2015; Shi et al., 2016; Lau et al., 2018b).  
MERS-CoV is transmitted by droplets through the respiratory route in the human population (Raj 
et al., 2014; Baseler et al., 2016; Otter et al., 2016). The disease can also be contracted from 
fomites. Figure 1.3 demonstrates the speculated transmission routes through which MERS-CoV 
can spread between populations. It is believed that bats infected camels with MERS-CoV-related 
viruses, from where it adapted and was transmitted to humans in the form of MERS-CoV (Milne-
Price et al., 2014). As different strains of MERS-CoV have been detected in patients that 
contracted the disease in the same region, it is possible that MERS-CoV-related viruses can 
also be transmitted from bats to other unknown intermediate hosts where slightly different 
mutations occur (Cotten et al., 2013; Milne-Price et al., 2014). Once contracted by humans, 
MERS-CoV can also spread in the population on occasion; however, human-to-human 
transmission has not often been reported (Milne-Price et al., 2014; Baseler et al., 2016).  
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Figure 1.3. The supposed transmission cycle of MERS-CoV. It has been speculated that ancestral 
viruses to MERS-CoV were transmitted from bats to camels, where genetic changes and host adaptation 
leads to the emergence of MERS-CoV, a virus that has acquired the ability to infect humans. Other routes 
of transmission from bats to humans remain unknown. Human-to-human transmission occurs occasionally 
(adapted from Milne-Price et al., 2014) (permission number for use of image: 4410530025102).  
1.2.1.3.6  Neoromicia capensis coronavirus 
NeoCoV was discovered in the South African bat species Neoromicia capensis (Ithete et al., 
2013; Corman et al., 2014) and has since been detected by other studies (Cronjé, 2017; 
Geldenhuys et al., 2018). NeoCoV is 85.5% genetically identical to MERS-CoV, meaning that, 
by definition, it belongs to the same virus species as MERS-CoV (de Groot et al., 2012). From 
this information it is inferred that NeoCoV is an ancestral virus to MERS-CoV (Corman et al., 
2014).  
The S1 subunit of NeoCoV is 45% similar to that of MERS-CoV and its S2 subunit is 87% 
identical to that of MERS-CoV (Ithete et al., 2013; Corman et al., 2014). The discrepancy 
between the S subunits indicates that NeoCoV is not the direct ancestor of MERS-CoV (Lau et 
al., 2018a). It also denotes that NeoCoV and MERS-CoV do not use the same cellular receptors 
and might not be able to infect the same cell types and/or hosts, which infers that NeoCoV 
would not have the ability to infect human cells (Lau et al., 2018a). This is further supported by 
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the fact that the S proteins of NeoCoV and PREDICT/PDF-2180, which cannot enter human 
cells, share 94% homology on an amino acid level (Anthony et al., 2017).  
The emergence of MERS-CoV is possibly the result of mutations and recombination events that 
NeoCoV and other ancestral viruses underwent by being transmitted from bats to different hosts 
such as camels and possibly other mammals that live in close contact with humans, from where 
it is finally transmitted to humans (Ithete et al., 2013; Corman et al., 2014, Geldenhuys et al., 
2018; Lau et al., 2018a). To better understand the host-switching and recombination events that 
gave rise to MERS-CoV, it is necessary to develop tools with which to study the different ways in 
which NeoCoV and MERS-CoV can infect cells. Isolating NeoCoV in cell culture would provide a 
manner in which NeoCoV infectivity and behaviour can be studied. However, as bat coronavirus 
isolation proves a challenge (Govorkova et al., 1996; Lednicky & Wyatt, 2012; Ge et al., 2013; 
Wei et al., 2017; Banerjee et al., 2018; Lau et al., 2018b), other approaches to study NeoCoV in 
vitro also need to be developed as a means of overcoming the issue of isolation.  
1.2.1.4  Viral receptors 
Various factors play a role in viral host tropism and cell susceptibility to viral infection. Among 
others, viruses require a direct contact with host cells in order to cause infection as well as an 
intracellular environment that allows for viral replication (i.e. the presence of viral promoters and 
enzymes involved in viral replication within host cells) (Baron et al., 1996). Receptors expressed 
on cell surfaces play a crucial role in viral host tropism (Baron et al., 1996; Masters, 2006; Milne-
Price et al., 2014). If a cell line expresses a receptor that allows the binding of a coronavirus, the 
cell line is susceptible to viral entry, after which infection can manifest.  
As mentioned previously, the coronavirus S protein is responsible for binding to and entry of 
host cells, provided that the cells of interest express the virus-specific receptors (Masters, 2006; 
Milne-Price et al., 2014). In the case of emerging viruses, the receptors to which these viruses 
attach are not always known. It is therefore not possible to determine whether the viruses can 
bind to cells with known receptors. Furthermore, this makes it impossible to determine which cell 
lines, mammalian species and organs are susceptible to infection by the emerging viruses of 
interest.  
Novel three-dimensional protein modelling methods exist to aid in predicting the molecular 
structure of an RBD in silico. These methods aid in determining whether the RBD of a protein 
will be able to bind to receptors based on the gene sequence encoding the protein. Furthermore, 
the methods also aid in determining which receptors the virus can utilise. Predicting the three 
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dimensional structure of a protein based on sequencing data is usually done by firstly comparing 
the RBD sequence to that of RBDs with known structures that are available in the protein data 
bank using specialised bioinformatics software (Moreno et al., 2017). Features of the secondary 
protein structure are then identified with the aid of algorithms available on web servers such as 
ENDscript 2 or SWISS-MODEL, after which the predicted structure can be compared to that of a 
virus of which the receptor has been identified by means of superimposition (Moreno et al., 
2017; Lau et al., 2018b). If there are major similarities between the RBDs of the two viruses, it 
indicates that the virus of interest would be able to utilise the same receptor (Anthony et al., 
2017; Moreno et al., 2017; Lau et al., 2018b). However, these studies do not provide information 
for viruses that are not closely related to viruses of which receptors have already been identified, 
nor does it prove that the virus of interest will be able to enter cells and establish an infection.  
In order to increase the feasibility of determining the host cell receptors for a specific virus that 
proves difficult to isolate in cell culture, methods to circumvent this issue have been established. 
Binding assays, in which envelope proteins of the virus of interest are expressed through 
baculovirus vectors, harvested and used to detect binding between the protein and receptors of 
interest, have been developed. However, these assays do not provide any information on how 
viral entry takes place (Tani et al., 2012).  
Another approach that has been developed is the use of viral pseudoparticles (Tani et al., 2012). 
Pseudotyped systems allow for studying the binding and entry of harmful viruses without the 
requirement of stringent biosafety measures and are combined with uncomplicated methods for 
detecting viral entry (Tani et al., 2012).  
1.2.2  Pseudotyped virus systems 
Pseudoparticles (also known as pseudotyped viruses or virus-like particles) are viral particles 
that have been modified to mimic a certain aspect of another virus (Cronin et al., 2005; Tani et 
al., 2012). Pseudotyped viruses entail the use of experimental systems in which a viral particle 
expresses the envelope gene(s) of other viruses (Cronin et al., 2005; Tani et al., 2012).  
There are two main reasons for using pseudoparticles instead of the actual virus of interest. 
Firstly, there are many viruses that, although attempted, have not been successfully isolated and 
cultivated in cell culture; as a result there is no virus available to use directly for the testing of 
host cell susceptibility or to investigate virus-cell interactions (Bartosch et al., 2003; Tani et al., 
2012). Secondly, the use of pseudoparticles lessens the danger of exposure to hazardous 
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agents in experimental settings; since they do not contain the virus of interest‟s genome, the risk 
of viral replication and/or mutation is eliminated (Cosset et al., 2009; Tani et al., 2012).  
Pseudoparticles are usually constructed to bear the surface proteins of another virus (Tani et al., 
2012). This is done in order to determine which host cell receptors are susceptible to binding to 
viruses of interest or the effect that viral binding and/or entry have on host cells (Tani et al., 
2012). Pseudoparticles have been used in determining host cell susceptibility to certain viruses 
and/or interactions between the two (Aiken, 1997; Wool-Lewis & Bates, 1998; Wang et al., 2004; 
Hanika et al., 2005; Hoffmann et al., 2013; Wang et al., 2016; Lau et al., 2018b), as well as to 
test samples for the presence of antibodies against specific viruses (Beels et al., 2008; Perera et 
al., 2013; Qiu et al., 2013), and also in the development of vaccines (Desjardins et al., 2009; 
Garrone et al., 2011; Schultz et al., 2012; Bolz et al., 2016; Wang et al., 2018).  
There are different methods of constructing pseudoparticles. One of the most widely used 
methods involves the use of a modified VSV∆G system that can be used to express foreign 
proteins. Another popular method to produce pseudoparticles is the use of plasmids carrying 
gene sequences which result in the formation of pseudoparticles when transcribed.  
Constructing a pseudotyped system such as the VSV*ΔG system usually involves the removal of 
the envelope protein gene from the genome of the virus to be used as the pseudoparticle and 
replacing it with a reporter gene such as luciferase, GFP or secreted alkaline phosphatase 
(SEAP) (Wool-Lewis & Bates, 1998; Tani et al., 2012). VSV is typically used for this method by 
removing the VSV-G gene from the viral genome, resulting in the formation of VSV*ΔG (Berger 
Rentsch & Zimmer, 2011; Tani et al., 2012; Hoffmann et al., 2013). These VSV*ΔG particles 
cannot replicate to form infectious particles, as it will produce particles that do not possess an 
envelope protein that can attach to host cells (Hoffmann, 2017). However, a stock of these 
particles can be generated through a process of trans-complementation (Hoffmann, 2017).  
Trans-complementation involves transfecting cells with plasmids containing VSV-G or using a 
cell line that can be induced to express VSV-G (such as BHK-21 [G43]) and infecting it with 
VSV*ΔG, resulting in the propagation of VSV*ΔG that expresses VSV-G but does not contain 
the gene itself (Hoffmann, 2017). These pseudoparticles can be used to infect cells expressing 
the foreign surface antigen of interest, usually generated by transfection with plasmids carrying 
the gene(s) of interest. After transfection with plasmids and subsequent infection with VSV*ΔG, 
pseudoparticles that contain the reporter gene and express the desired surface antigen on their 
surfaces are released from the cells (Berger Rentsch & Zimmer, 2011; Tani et al., 2012; 
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Hoffmann et al., 2013). The process of pseudoparticle production using the VSV*ΔG system is 
diagrammatically explained in Figure 1.4. The newly-formed pseudoparticles can then be 
harvested and used in the experimental procedures mentioned previously, the reporter gene(s) 
aiding in visualising whether infection was successful (Hoffmann et al., 2013).  
 
Figure 1.4. Pseudoparticle production using the VSV*ΔG system. Cells used for the production of 
pseudoparticles are transfected with plasmids carrying the surface antigen of interest‟s gene sequence. 
After transfection, cells are infected with the VSV*ΔG pseudoparticles and when the pseudoparticles bud 
from the cells, which are expressing the foreign surface antigen, the particles carry the surface antigen.  
The propagation of pseudoparticles can also be achieved through the use of various plasmids 
carrying the genes required (Wool-Lewis & Bates, 1998; Giroglou et al., 2004; Simmons et al., 
2004; Belouzard et al., 2009; Wang et al., 2016; Lau et al., 2018b; Wang et al., 2018). The triple 
plasmid transfection assay involves transfecting cells with three plasmids in order to produce 
pseudoparticles (Wool-Lewis & Bates, 1998; Giroglou et al., 2004; Simmons et al., 2004; 
Belouzard et al., 2009; Wang et al., 2016; Lau et al., 2018b; Wang et al., 2018). One plasmid 
contains the group-specific antigen and polymerase gene sequences of a retrovirus such as 
human immunodeficiency virus or murine leukemia virus, a second plasmid carries the gene 
sequence for a reporter gene and another vector has the gene sequence of the surface 
protein(s) of interest (Wool-Lewis & Bates, 1998; Giroglou et al., 2004; Simmons et al., 2004; 
Belouzard et al., 2009; Wang et al., 2016; Lau et al., 2018b; Wang et al., 2018). The transfected 
cells express the desired surface protein(s), pseudoparticles carrying the reporter proteins 
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assemble within the cells with the aid of the retroviral proteins and bud from cells bearing the 
desired surface protein(s) (Wool-Lewis & Bates, 1998; Giroglou et al., 2004; Simmons et al., 
2004; Belouzard et al., 2009; Wang et al., 2016; Lau et al., 2018b; Wang et al., 2018).  
Another method to construct strictly plasmid-based pseudoparticles involves the transfection of 
cells with a plasmid(s) carrying the genetic sequences for the structural proteins of the virus of 
interest (Mortola & Roy, 2004). Reporter genes can be included in the plasmids for in vitro 
visualisation purposes. Viral capsids are assembled and released, making it possible to harvest 
the pseudoparticles that resemble the virus of interest, but does not contain any genetic material 
(Mortola & Roy, 2004).  
Wang et al. (2016) made use of a lentivirus-based pseudotyped system in order to produce 
pseudoparticles expressing the S proteins of SARS-CoV, MHV, HCoV-229E, HCoV-OC43, IBV, 
BCoV, porcine epidemic diarrhoea virus (PEDV) or TGEV. These pseudoparticles were used to 
test the susceptibility of HEK (strain 293), African green monkey kidney (Vero-CCL-81), human 
liver (Huh-7), porcine kidney (PK) (strain 15) and feline kidney (CCL94) cells by monitoring the 
viruses‟ infectivity for each cell type. It was found that pseudoparticles bearing the S protein of 
SARS-CoV were able to infect only HEK-293 cells (Wang et al., 2016). HEK-293 cells were also 
susceptible to infection by pseudoparticles expressing the S proteins of HCoV-OC43, IBV, 
BCoV, PEDV and TGEV (Wang et al., 2016). Furthermore, it was found that pseudotyped 
viruses bearing the PEDV- and TGEV S proteins were able to infect Vero-CCL-81, Huh-7 and 
PK-15 cells, but CCL94 cells were only susceptible to infection by TGEV-S-bearing 
pseudoparticles (Wang et al., 2016).  
In 1998, Wool-Lewis and Bates constructed pseudoparticles expressing the glycoprotein of the 
Ebola viruses using a murine leukemia virus-based system. The pseudoparticles were used to 
test the susceptibility of various cell lines, including HEK-293, Swiss albino mouse embryo 
fibroblasts (NIH 3T3), human cervical carcinoma (HeLa), Vero, MDCK, Madin-Darby bovine 
kidney (MDBK), PK-15, human B cell precursor leukemia (Nalm-6), human B lymphoblast 
(Daudi), human T lymphocyte (HUT-78) and mouse B lymphocyte (WEHI) cells. It was found 
that the pseudoparticles were not able to infect any of the lymphoid cells, an observation that 
concurs with the literature (Wool-Lewis & Bates, 1998). Pseudoparticles were successful in 
entering all other tested cell lines, including cells that have never been successfully infected in 
vivo, such as fibroblasts originating from Swiss albino mice embryos. This suggests that Ebola 
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viruses are able to enter these cells, but that the spread of infection is inhibited by host immune 
systems (Wool-Lewis & Bates, 1998).  
The current study was based on work previously done by Hoffmann et al. (2013). The research 
group produced pseudoparticles expressing the surface proteins of SARS-CoV, Marburg virus, 
Sendai virus, bovine respiratory syncytial virus and influenza virus strains H1N1, H7N7 and 
H9N2. Various cell lines, including Rousettus aegyptiacus kidney (RoNi/7), Hypsignathus 
monstrosus kidney (HypNi/1.1), Epomops buettikoferi kidney (EpoNi/22.1), Rhinolophus alcyone 
lung (RhiLu/1.1), Carollia perspicillata lung (CpLu) and Tadarida brasiliensis lung (Tb 1 Lu) cells 
were inoculated with the pseudoparticles. Infection was monitored with fluorescence microscopy 
detecting GFP expression or measuring luciferase activity. None of the cell lines were 
susceptible to infection with pseudoparticles bearing the SARS-CoV S protein. Furthermore, it 
was found that all cells lines were susceptible to infection with Marburg virus, Sendai virus and 
bovine respiratory syncytial virus. Infection of Ro/Ni/7, HypNi/1.1, EpoNi/22.1 and CpLu cells 
with the three influenza viruses resulted in high numbers of infected cells, whereas fewer 
infected cells were observed when infecting RhiLu/1.1 and Tb 1 Lu cells.  
The characterisation of viral proteins responsible for binding to and fusing with host cells, and 
the investigation of host tropism, play significant roles in the detection and possible prevention of 
viral spread. Investigating the host ranges of emerging viruses and understanding the factors 
that contribute to zoonotic emergence is beneficial to possible future outbreak preparedness.  
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CHAPTER 2 
2  Materials & Methods 
2.1  Ethics 
Ethical clearance was obtained for the testing of bat faecal samples for coronaviruses from 
Stellenbosch University's Research Ethics Committee: Animal Care and Use (Protocol number 
SU-ACUD16-00008). The letter of ethics approval can be found in Addendum A.  
2.2  Materials 
A comprehensive list of the consumables, equipment and software used is provided in Table B.1 
in Addendum B. Table 2.1 provides a list of all the kits and reagents used in this study.  
Table 2.1. List of kits and reagents used.  
Kit/reagent Catalogue number Company Country 
Reagents for general use 
Dulbecco‟s Phosphate 
Buffered Saline 
L0615-500 Biowest France 
BioWhittaker Dulbecco‟s 
Phosphate Buffered 
Saline 
BE17-512F Lonza Group Switzerland 
BioWhittaker Phosphate 
Buffered Saline 
BE17-516Q Lonza Group Switzerland 
Dulbecco‟s Phosphate 
Buffered Saline 
D8537-500ML Sigma-Aldrich 
United States of 
America (USA) 
Gibco Dulbecco‟s 
Phosphate Buffered 
Saline 
14190-094 Thermo Fisher Scientific USA 
BioWhittaker Phosphate 
Buffered Saline (10×) 
BE17-517Q Lonza Group Switzerland 
Ethyl alcohol, pure E7023-500ML Sigma-Aldrich USA 
Kits and reagents for molecular methods 
NucleoSpin RNA Virus 
kit 
740956.250 Macherey-Nagel Germany 
Maxima Reverse 
Transcriptase kit 
EP0743 Thermo Fisher Scientific USA 
dNTP Mix BIO-39029 Bioline United Kingdom (UK) 
RiboLock RNase EO0381 Thermo Fisher Scientific USA 
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Inhibitor 
Maxima Hot Start Taq 
DNA Polymerase kit 
EP0601 Thermo Fisher Scientific USA 
OneTaq Hot Start DNA 
Polymerase kit 
M0481 New England Biolabs USA 
TopVision Agarose 
Tablets 
R2801 Thermo Fisher Scientific USA 
Sodium hydroxide 
pellets 
AB006498.500 Merck USA 
Boric acid AC000165.500 Merck USA 
Pronasafe Nucleic Acid 
Staining solution (20 
000×) 
CK130 Laboratorios CONDA Spain 
GeneRuler 1kb DNA 
Ladder 
SM0311 Thermo Fisher Scientific USA 
6× DNA Loading Dye R0611 Thermo Fisher Scientific USA 
NucleoSpin Gel and 
PCR Clean-up kit 
740609.250 Macherey-Nagel Germany 
BigDye Terminator v3.1 
Cycle Sequencing kit 
4336917 Thermo Fisher Scientific USA 
BigDye Xterminator 
Purification kit 
4376487 Thermo Fisher Scientific USA 
InsTAclone PCR 
Cloning kit 
K1214 Thermo Fisher Scientific USA 
Mix & Go Competent 
Cells - Strain JM109 
T3005 Zymo Research USA 
LB Broth 61748 Fluka BioChemika Switzerland 
Agar A7002-1KG Sigma-Aldrich USA 
Ampicillin Sodium A0104 
Melford Biolaboratories 
Ltd. 
UK 
IPTG I6758-5G Sigma-Aldrich USA 
X-Gal R0404 Thermo Fisher Scientific USA 
One Shot Top 10 
Chemically Competent 
Cells 
C404010 Thermo Fisher Scientific USA 
SOC Medium S2630 
Melford Laboratories 
Ltd. 
UK 
GeneJET Plasmid K0503 Thermo Fisher Scientific USA 
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Miniprep kit 
GeneJET Plasmid 
Midiprep kit 
K0482 Thermo Fisher Scientific USA 
EcoRI R0101M New England Biolabs USA 
MinElute PCR 
Purification kit (250) 
28006 Qiagen Germany 
TranscriptAid T7 High 
Yield Transcription kit 
K0441 Thermo Fisher Scientific USA 
Invitrogen PureLink RNA 
Mini kit 
12183018A Thermo Fisher Scientific USA 
β-Mercaptoethanol, 
Molecular Biology Grade 
44-420-3250ML Calbiochem™ USA 
Qubit RNA HS Assay kit Q32852 Thermo Fisher Scientific USA 
SensiFAST Probe No-
ROX One-Step kit 
BIO-76005 Bioline UK 
Kits and reagents for cell culture 
DMEM High Glucose L0102-500 Biowest France 
BioWhittaker DMEM BE12-614F Lonza Group Switzerland 
Penicillin-Streptomycin 
Solution 100× 
L0022-100 Biowest France 
BioWhittaker Pen-Strep BW17-602E Lonza Group Switzerland 
Gibco Pen Strep 15140-122 Thermo Fisher Scientific USA 
BioWhittaker NEAA 
100× 
BE13-114E Lonza Group Switzerland 
BioWhittaker Na 
pyruvate (100 mM 
solution) 
BE13-115E Lonza Group Switzerland 
BioWhittaker L-
glutamine 
BE17-605F Lonza Group Switzerland 
Gibco L-glutamine 
200mM (100×) 
25030-032 Thermo Fisher Scientific USA 
Fetal Bovine Serum S181Y-50 Biowest France 
Gibco Fetal Bovine 
Serum 
10499-044 Thermo Fisher Scientific USA 
Trypsin-EDTA 1× in PBS L0940-500 Biowest France 
BioWhittaker Trypsin 
10× (diluted to 1×) 
BE02-007E Lonza Group Switzerland 
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Gibco Trypsin/EDTA 
solution (1×) 
R-001-100 Thermo Fisher Scientific USA 
Accutase L0950-100 Biowest France 
Dimethyl Sulfoxide D8418-50ML Sigma-Aldrich USA 
100mg Amphotericin B - 
solubilized 
A9528-100MG Sigma-Aldrich USA 
Gibco OptiPRO Serum-
Free Medium 
12309-050 Thermo Fisher Scientific USA 
Mifepristone M8046-100MG Sigma-Aldrich USA 
Formaldehyde Solution 
(40% w/v) 
N/A 
BDH Laboratory 
Supplies Limited 
UK 
Formaldehyde Solution SAAR2436020LP Merck USA 
Invitrogen Lipofectamine 
2000 
11668-027 Thermo Fisher Scientific USA 
DAPI (4‟,6-diamidino-2-
phenylindole, 
dihydrochloride) 
D1306 Thermo Fisher Scientific USA 
ProLong Gold antifade 
reagent 
P10144 Thermo Fisher Scientific USA 
 
Bat faecal samples that were screened for coronaviruses were previously collected as part of a 
bigger research project by collaborators at the University of KwaZulu-Natal. These collaborators, 
under the guidance of Prof. M. Schoeman, are trained zoologists and ecologists who sourced 
these samples with the relevant permits. Details on these samples can be found in Table C.1 in 
Addendum C.  
The primer and probe sequences used for reverse transcription, PCR and RT-qPCR assays are 
listed in Table 2.2.  
Table 2.2. Primers and probe used in reverse transcription, PCR and RT-qPCR assays.  
Primers used for reverse transcription 
Primer name Catalogue number Company Country 
Random hexamer primers BIO-38028 Bioline UK 
Primers used in coronavirus screening PCR 
Primer name Primer sequence (5’ - 3’) 
PCAs4 CACACAACACCTTCATCAGATAGAATCATCA 
Gr1Sp Gr1Sp_F1 TTCTTTGCACAGAAGGGTGATGC 
Stellenbosch University  https://scholar.sun.ac.za
26 
 
Gr1Sp_F2 CTTTGCACAAAAAGGTGATGCWGC 
RGU_2cError! 
ookmark not 
defined. 
RGU_2c_F1 TTYGCDCAAGATGGAMATGCTGC 
RGU_2c_F2 TTYGCDCAAGATGGTMATGCTGC 
SP3080 F1 CTTCTTCTTTGCTCAGGATGGCAATGCTGC 
SP3374 F3 CTATAACTCAAATGAATCTTAAGTATGC 
Primers used in Mycoplasma screening 
Primer name Primer sequence (5’ - 3’) 
Myco-5-1 CGCCTGAGTAGTACGTTCGC 
Myco-5-2-1 CGCCTGAGTAGTACGTACGC 
Myco-5-2-2 TGCCTGAGTAGTACATTCGC 
Myco-5-2-3 TGCCTGGGTAGTACATTCGC 
Myco-5-5 CGCCTGGGTAGTACATTCGC 
Myco-5-6 CGCCTGAGTAGTATGCTCGC 
Myco-3-1 GCGGTGTGTACAAGACCCGA 
Myco-3-2 GCGGTGTGTACAAAACCCGA 
Myco-3-3 GCGGTGTGTACAAACCCCGA 
Primers used in sequencing PCR of cloning products 
Primer name Primer sequence (5’ - 3’) 
M13 Forward GTAAAACGACGGCCAG 
M13 Reverse CAGGAAACAGCTATGAC 
T7 promoter primer TAATACGACTCACTATAGGG 
Primers used in RT-qPCR 
Primer name Primer sequence (5’ - 3’) 
2c_RdRp_qPCR_F GTGYGCTCAAGTGYTWAGTGARTATGT 
2c_RdRp_qPCR_R CCATTAGCRCYCATAAGTGCACTAACA 
Probe used in RT-qPCR 
Probe name Probe sequence (5’ - 3’) 
2c_RdRp_qPCR_P FAM-GCWTAYGCC/ZEN/AATAGTGTYTTTAACAT/3IABkFQ 
 
All PCR primers, RT-qPCR primers and the RT-qPCR probe were purchased from Integrated 
DNA Technologies (IDT) (USA). The primers used for sequencing of cloned products were 
included in the InsTAclone PCR Cloning kit.  
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Primer PCAs4 was used as reverse primer in all screening PCR reactions. Both of the Gr1Sp 
and RGU_2c primers were used in equimolar dilutions in the screening PCRs.  
Gr1Sp primers were designed to detect alphacoronaviruses; RGU_2c primers were designed for 
the detection of MERS-related betacoronaviruses; and SP3080 F1 and SP3374 F3 were 
designed for the detection of SARS-related betacoronaviruses. The Gr1Sp, SP3080 F1 and 
SP3374 F3 primers were designed by Drexler et al. (2010); RGU_2c primers were designed by 
Dr N. Ithete (Cronjé, 2017). Primer PCAs4 was originally designed by de Souza Luna et al. 
(2007) and has subsequently been used as the reverse primer for other coronavirus screening 
PCRs.  
The primers and probe for the RT-qPCR targeting MERS-related betacoronaviruses were 
designed by Dr N. Ithete.  
The primers used in the screening for Mycoplasma contamination were designed by Wirth et al. 
(1994) for the detection of M. orale, M. arginini, M. hyorhinis, M. fermentans, M. hyopneumoniae, 
M. salivarium, M. gallisepticum, M. pneumoniae, M. hominis, M. bovis, M. californicum, M. 
bovigenitalium, M. bovoculi, M. mycoides, M. bovirhinis, M. alkalescens, M. canadense, M. 
synoviae, M. verecundum, M. gatae, M. meleagridis, M. gallinarum, M. iowae, M. pullorum, M. 
gallinaceum, M. gallopavonis, M. arthridis, Acholeplasma laidlawii and A. axanthum. Equimolar 
dilutions with a final concentration of 10 µM of each primer were made of the forward primers 
(designated Myco-5) and of the reverse primers (designated Myco-3), respectively.  
A gBlocks Gene Fragment (IDT) of a region of the M. bovis genome (GenBank accession 
number: CP002188) (positions 321 910 to 322 530) was purchased from IDT and used as a 
positive control when screening for Mycoplasma contamination.  
The pCG1 plasmids containing inserts of interest for use in the preparation of pseudoparticles 
were obtained from collaborators at the Charité University Hospital in Berlin, Germany. The 
inserts and designated names of these plasmids can be found in Table 2.3.  
Table 2.3. Plasmids used for pseudoparticle preparation.  
Insert Designated name of plasmid with insert 
VSV-G pCG1-VSV-G 
No insert (empty vector [EV]) pCG1-EV 
MERS-CoV S protein pCG1-MERS-S 
NeoCoV S protein pCG1-NCV-S 
SARS-CoV S protein pCG1-SARS-S 
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Plasmid pCG1-VSV-G was used to generate a positive control, while pCG1-EV was used for 
production of a negative control. The other three plasmids aided in producing pseudoparticles 
expressing the three coronaviruses‟ S proteins.  
2.3  Methods 
2.3.1  Molecular methods 
2.3.1.1  Screening of bat faecal samples for NeoCoV 
2.3.1.1.1  Homogenisation of bat faecal samples 
Bat faecal samples collected from different bat species in 2017 and stored in viral transport 
medium (VTM) (consisting of Dulbecco's Modified Eagle Medium [DMEM] supplemented with 
1% v/v amphotericin B and 1% v/v penicillin-streptomycin) were homogenised according to the 
protocol described by Dr N. Cronjé (2017). This was achieved by adding one faecal pellet 
(weight ≈ 30 mg) from each sample (see Table C.1 in Addendum C) to separate 2 ml 
microcentrifuge tubes each containing five 2.4 mm metal beads and 1 ml phosphate buffered 
saline (PBS). The microcentrifuge tubes were placed in the TissueLyser LT and oscillated for 
five minutes at 50 Hz. After oscillation, the microcentrifuge tubes were centrifuged at 12 000 × g 
for two minutes and the supernatants transferred to sterile microcentrifuge tubes. The 
homogenates were stored at -80°C.  
2.3.1.1.2  Extraction of viral RNA from homogenised bat faecal samples and cell 
culture supernatant 
RNA was extracted from homogenised bat faecal samples (section 2.3.1.1.1) and from 
supernatant removed from cell cultures inoculated with virus-positive homogenate (refer to 
section 2.3.3) using the NucleoSpin RNA Virus kit. The manufacturer‟s protocol was followed. 
Briefly, 150 µl of homogenised sample or cell culture supernatant was mixed with 600 µl buffer 
RAV1 containing 1% v/v carrier RNA and incubated at 56°C. Thereafter, 600 µl ethanol (96% 
v/v) was added to the mixture, followed by loading up to 700 µl of sample mixture to a provided 
NucleoSpin RNA Virus Column in a collection tube. The column was centrifuged at 8 000 × g for 
one minute, the flow-through discarded and the centrifugation repeated after loading the 
remaining sample mixture onto the column. Washing steps were performed by adding 500 µl 
wash buffer RAW and 600 µl wash buffer RAV3 onto the column in subsequent steps, 
centrifuging the column at 8 000 × g for one minute after each loading step. After discarding the 
flow-through, 200 μl wash buffer RAV3 was added to the column, followed by centrifugation at 
11 000 × g for five minutes. Flow-through was discarded, after which the column was centrifuged 
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for an additional two minutes at 11 000 × g. The column was placed in a 1.5 ml microcentrifuge 
tube and 50 μl nuclease-free water pre-heated to 70°C was added to the column and incubated 
at room temperature for one minute. The tube with the column was centrifuged at 11 000 × g for 
one minute and eluted RNA was stored at -80°C.  
2.3.1.1.3  Reverse transcription 
Complementary deoxyribonucleic acid (cDNA) strands was generated using RNA extracted from 
bat faecal samples as templates (section 2.3.1.1.2). The cDNA was subsequently used in the 
screening PCR reactions.  
The Maxima Reverse Transcriptase kit was used and the reactions were prepared and 
incubated as shown in Tables 2.4 and 2.5.  
Table 2.4. Preparation of the first reaction mixture for reverse transcription reactions.  
First reaction mixture 
Component Volume (µl) 
RNA template  10.0 
Random hexamer primer (10 µM) 1.5 
Deoxyribonucleotide triphosphate (dNTP) mix (10 mM each) 1.0 
Nuclease-free water 2.0 
Total  14.5 
 
Reactions were incubated at 65°C for five minutes, after which they were chilled on ice for one 
minute. Thereafter, the second reaction mixture, as seen in Table 2.5, was added to each 
reaction and reactions were incubated according to the parameters in Table 2.5.  
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Table 2.5. Preparation of the second reaction mixture and incubation of reverse transcription 
reactions.  
Second reaction mixture 
Component Volume (µl) 
5× RT Buffer 4.0 
RiboLock RNase inhibitor (40 U/µl) 0.5 
Maxima Reverse Transcriptase (200 U/µl) 1.0 
Total 5.5 
Incubation 
Temperature (°C) Time (minutes) 
25 10 
50 30 
85   5 
  4  ∞ 
 
Products of reverse transcription were stored at -20°C until further use.  
2.3.1.1.4  Amplification of cDNA 
The cDNA obtained through reverse transcription (section 2.3.1.1.3) was screened using a PCR 
targeting a region of roughly 900 base pairs (bp) of the RNA-dependent RNA polymerase 
(RdRp) gene of certain alphacoronaviruses, MERS-related betacoronaviruses and SARS-related 
betacoronaviruses. Four different primer sets (Table 2.2) (Drexler et al., 2010; Cronjé, 2017) 
were used for screening; i.e. four reactions were prepared for each sample that was screened, 
each using a different set of primers. The PCRs will hereafter be referred to as PCR Gr1Sp, 
PCR RGU_2c, PCR SP3080 F1 and PCR SP3374 F3. The reverse primer (PCAs4) binds to the 
NeoCoV genome (GenBank accession number: KC869678) from positions 15 689 to 15 719. 
The Maxima Hot Start Taq DNA Polymerase kit was used and reactions were prepared as 
described in Table 2.6.  
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Table 2.6. Reaction mixture for PCR reactions.  
Component Volume (µl) 
10× Hot Start PCR Buffer 2.5 
dNTP mix (10 mM each) 0.5 
Forward primer 1 (10 µM) 1.25 
Forward primer 2 (where applicable) (10 µM) 1.25 
Reverse primer (10 µM) 1.25 
MgCl2 (25 mM) 1.5 
cDNA template 2.5 
Maxima Hot Start Taq DNA Polymerase (5 U/µl) 0.125 
Nuclease-free water   to 25.0 
Total  25.0 
 
Thermal cycling of these reactions was done according to the parameters described in Table 
2.7. Thermal cycling was done at maximum ramp speed. Ten touchdown cycles, decreasing by 
1°C in each annealing step, were followed for the first stage of the PCR thermal cycling.  
Table 2.7. Thermal cycling parameters for PCR reactions.  
Temperature (°C) Time  
95   4 minutes  
95 20 seconds  
60 50 seconds  
72   1 minute  
95 20 seconds  
54 50 seconds ×50 cycles 
72   1 minute  
72   5 minutes  
  4 ∞  
 
Products of amplification were stored at -20°C until further use.  
2.3.1.2  Screening cell cultures for Mycoplasma contamination 
Mycoplasma contamination poses a threat to cell cultures, resulting in unreliable results when 
transfecting and infecting cells (Rottem & Barile, 1993; Uphoff & Drexler, 2002a; Uphoff & 
Drexler, 2004). Aliquots of supernatants were taken off cell cultures prior to transfection and 
infection experiments (refer to sections 2.3.3 – 2.3.4) and stored at -20°C until required. These 
 ×10 touchdown 
cycles (-1°C) 
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aliquots were subsequently used for screening for Mycoplasma contamination using a method 
described by Uphoff and Drexler (2002a; 2004), which detects a 500 bp fragment of the 
Mycoplasma genome by PCR. This was achieved by using the OneTaq Hot Start DNA 
Polymerase kit according to the manufacturer‟s instructions.  
Supernatant was removed from cell cultures prior to transfection/infection, heated to 95°C for 
five minutes to lyse cells and centrifuged at 16 000 × g for two minutes to remove cell debris. 
Thereafter, 2 μl of the supernatant was added to the reaction mixtures to act as template. 
Reaction mixtures were prepared according to the method described in Table 2.8. The 620 bp 
gBlocks Gene Fragment of the M. bovis genome was used as positive control, of which 5 μl with 
a concentration of 10 ng/µl was used as template.  
Table 2.8. Reaction mixtures for Mycoplasma screening PCR reactions.  
Component Volume (µl) 
5× OneTaq Standard Reaction Buffer 5.0 
dNTPs (10 mM each) 0.5 
Forward primer mix (10 µM each) 0.5 
Reverse primer mix (10 µM each) 0.5 
OneTaq Hot Start DNA Polymerase (5 U/µl) 0.125 
Template DNA 1-1000 ng 
Nuclease-free water to 25.0 
Total 25.0 
 
Thermal cycling of the reactions was then performed according to the parameters described in 
Table 2.9.  
Table 2.9. Thermal cycling parameters for Mycoplasma screening PCR reactions.  
Temperature (°C) Time  
94 30 seconds  
94 30 seconds  
50 30 seconds ×5 cycles 
68 35 seconds  
94 15 seconds  
56 15 seconds ×30 cycles 
68 30 seconds  
68 10 minutes  
  4 ∞  
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2.3.1.3  Agarose gel electrophoresis and visualisation of amplified products 
Agarose gel electrophoresis was performed to visualise DNA amplified by PCR. This was done 
by adding TopVision Agarose tablets to 1× sodium boric acid (SB) buffer prepared as described 
by Brody and Kern (2004) at a concentration of 1% w/v. After dissolving the agarose tablet, the 
mixture was boiled and swirled to mix thoroughly. After cooling slightly, Pronasafe Nucleic Acid 
Staining solution (20 000×) was added to the mixture at a concentration of 7% v/v. This was 
poured in a gel tray and allowed to set before submerging in 1× SB buffer in an electrophoresis 
tank.  
Samples were loaded into the wells after mixing 1 µl 6× loading dye with 4.5 µl PCR product. 
Furthermore, 3 µl GeneRuler 1kb DNA Ladder was mixed with 1 µl 6× loading dye and added to 
the gel as a reference sizing marker. Electrophoresis was carried out for 40 minutes at 90 volts. 
Gels were visualised using the UVITec Gel Documentation System operated by UVIproChemi 
software. Amplified products of the desired sizes, as can be seen in Table 2.10, were processed 
further in order to obtain genomic sequences of the amplified products.  
Table 2.10. Desired sizes of amplified DNA for all PCRs.  
PCR Desired product size (bp) 
PCR Gr1Sp 974 
PCR RGU_2c 974 
PCR SP3080 F1 974 
PCR SP3374 F3 682 
Mycoplasma screening PCR 500 
2.3.1.4  Purification of PCR products 
The NucleoSpin Gel and PCR Clean-up kit was used to purify the desired PCR products as 
determined by agarose gel electrophoresis (section 2.3.1.3). Products were purified according to 
the manufacturer‟s protocol. The complete PCR product was mixed with double the volume of 
binding buffer NTI and loaded onto a provided NucleoSpin Gel and PCR Clean-up Column in a 
collection tube. The column was centrifuged at 11 000 × g for 30 seconds. The flow-through was 
discarded and 700 μl wash buffer NT3 was added to the column. The column was centrifuged at 
11 000 × g for one minute, flow-through was discarded and the washing step was repeated. The 
column was centrifuged at 11 000 × g for one minute after the second washing step, after which 
the column was placed in a 1.5 ml microcentrifuge tube. The column was incubated with 20 μl 
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elution buffer NE for one minute and centrifuged at 11 000 × g for one minute. Eluted products 
were stored at -20°C until further use.  
2.3.1.5  Spectrophotometric analysis 
The concentration of genomic material in purified samples was determined with the NanoDrop 
ND-1000 Spectrophotometer V3.1.0 before use in subsequent reactions. ND-1000 V3.1.0 
software was used to analyse and capture data. First, the optical surfaces of the instrument were 
wiped down with ethanol and distilled water, after which 1 µl nuclease-free water was loaded 
onto the instrument to initialise it. After initialisation, optical surfaces were cleaned with ethanol 
and distilled water; thereafter, 1 µl of the substance used for elution of the specific sample was 
loaded onto the instrument and a blank measurement was taken. The optical surfaces were 
cleaned with ethanol and water, after which the concentration of genomic material of each 
sample was measured. This was achieved by loading 1 µl of sample onto the instrument and 
taking a measurement using the ND-1000 V3.1.0 software. Optical surfaces were cleaned with 
ethanol and water after each measurement.  
2.3.1.6  Sequencing PCR and analysis 
Purified DNA fragments obtained through PCR, as well as purified plasmids (refer to section 
2.3.1.10) and cultures yielding products during Mycoplasma screening (section 2.3.1.2), were 
sequenced by the Sanger method using the BigDye Terminator v3.1 Cycle Sequencing kit 
according to the manufacturer‟s protocol. Reaction mixtures were prepared as described in 
Table 2.11.  
Table 2.11. Reaction mixture for sequencing reactions.  
Component Volume (µl) 
Nuclease-free water 2 
BigDye Terminator v1.1, v3.1 5× Sequencing Buffer 3 
BigDye Terminator v3.1 Cycle Sequencing RR-100 1 
DNA template (10 ng/µL) 2 
Primer (2.5 µM) 2 
Total 10 
 
Separate reactions were prepared with each of the primers used to amplify each sample. Thus, 
two reactions, one with a forward primer and another with a reverse primer, were prepared for 
samples amplified with PCRs SP3080 F1 and SP3374 F3, and three were prepared for products 
of PCRs Gr1Sp and RGU_2c to accommodate the second forward primer. For the sequencing of 
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plasmids, a forward and a reverse primer were selected based on the binding sites available on 
the plasmid; i.e. the M13 primers were used when sequencing pTZ57R/T, whereas the M13 
forward primer and the T7 promoter primer were used when sequencing pCG1.  
The reactions underwent thermal cycling at the parameters detailed in Table 2.12, setting the 
thermal cycler to maximum ramp speed.  
Table 2.12. Thermal cycling parameters for sequencing reactions.  
Temperature (°C) Time  
96   1 minute  
95 10 seconds  
54   5 seconds ×30 cycles 
60   4 minutes  
  4 ∞  
 
After thermal cycling, reactions were purified using the BigDye Xterminator Purification kit. 
Briefly, 45 µl of SAM Solution and 10 µl Xterminator Solution Buffer was added to each reaction 
before vortexing for 30 minutes. Thereafter, the DNA fragments were sent to Stellenbosch 
University‟s Central Analytical Facility (CAF) for sequencing electrophoresis. The sequencing 
data files were analysed and contiguous sequences were assembled with the molecular biology 
analysis tool Geneious R10 bioinformatics software. Genomic similarity was determined by using 
the Basic Local Alignment Search Tool (BLAST) online tool developed by the National Center for 
Biotechnology Information (NCBI) (USA) (available online at 
https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
Sequences obtained from sequencing of the PCR products were used to identify a NeoCoV-
related sample to be used in attempts at isolating NeoCoV in cell culture (refer to section 2.3.3). 
Sequencing of the plasmids was performed to confirm the presence of the desired inserts.  
2.3.1.7  Ligation 
In order to generate in vitro transcribed RNA positive controls for RT-qPCR, a purified PCR 
product obtained from a NeoCoV-screening positive sample (purified PCR RGU_2c product of 
sample 23) was cloned into pTZ57R/T vector (Figure 2.1) using the InsTAclone PCR cloning kit 
according to the manufacturer‟s protocol. The reaction was prepared according to the guidelines 
in Table 2.13.  
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Figure 2.1. pTZ57R/T vector map indicating restriction sites, genes and cloning region (Thermo 
Fisher Scientific, 2016).  
Table 2.13. Reaction mixture for ligation reaction.  
Component Volume (µl) 
Nuclease-free water   to 30 
Vector pTZ57R/T (55 ng/µl) 3 
5× Ligation Buffer 6 
DNA fragment (17 ng/100 bp)  166 ng 
T4 DNA Ligase 1 
Total 30 
 
The reaction was incubated at the parameters developed by Dr R. Fisher (2016) described in 
Table 2.14.  
Table 2.14. Incubation parameters for ligation reaction.  
Temperature (°C) Time 
25   2 hours 
  4 16 hours 
75   5 minutes 
  4   ∞ 
 
Products were stored at -20°C after incubation.  
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2.3.1.8  Bacterial transformation of plasmids 
Agar was prepared before transformation experiments. This was done by adding 7.5 g agar to 
500 ml distilled water and autoclaving it. Once the agar mixture had reached ~50°C, 0.05 mg/ml 
ampicillin was added to the mixture. The mixture was then poured onto agar plates, 25 ml agar 
per plate, and stored at 4°C until needed.  
2.3.1.8.1  Transformation using Mix & Go Competent Cells 
Mix & Go Competent Cells (Strain JM109) were transformed with the pTZ57R/T clone containing 
the NeoCoV RdRp region insert according to the manufacturer‟s instructions. Briefly, 1.25 µl of 
ligation product prepared through the method described in section 2.3.1.7 was mixed with 25 µl 
competent cells and incubated on ice for five minutes. Thereafter, the cells were spread on a 
pre-warmed agar plate along with 40 µl isopropyl β-D-1-thiogalactopyranoside (IPTG) (1 mM) 
and 16 µl 5-bromo-4-chloro-3-indolyl -D-galactopyranoside (X-gal) (2% w/v). The plate was 
incubated overnight at 37°C.  
The pTZ57R/T plasmid facilitates blue-white colony screening as a visual means to assess 
successful transformation. Colonies containing inserts were white in colour due to blue-white 
screening, which is observed when an insert disrupts the lacZ gene on the plasmid. If the lacZ 
gene was still intact, the colony would be able to utilise the X-gal on the plate, leading to the 
formation of a blue colour. Therefore, the formation of a blue colony would mean that ligation 
was unsuccessful, and a white colony that ligation was successful.  
2.3.1.8.2  Transformation using One Shot Top 10 Chemically Competent Cells 
One Shot Top 10 Chemically Competent Cells were transformed with the plasmids to be used in 
the preparation of the pseudoparticles (Table 2.3; refer to section 2.3.4.2.1). The manufacturer‟s 
protocol was followed. Briefly, a vial of cells was thawed on ice for each of the plasmids and 1 μl 
of plasmid DNA was mixed with the cells in the corresponding vial. Cells were incubated on ice 
for 30 minutes, after which cells were heat-shocked at 42°C for 30 seconds. Cells were 
subsequently incubated on ice for two minutes and 250 μl of SOC Medium was added to each 
vial. Vials were incubated at 37°C, shaking at 225 rpm for one hour. Cells were then spread on 
pre-warmed agar plates along with 40 µl IPTG (1 mM) and 16 µl X-gal (2% w/v). Plates were 
incubated at 37°C overnight.  
The plasmid pCG1 contains the lacZ gene. Blue-white colony screening, as described in section 
2.3.1.8.1, was used for the selection of competent cells transformed with plasmids that contain 
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inserts. A blue colony was selected in the case of plasmid pCG1-EV, as the plasmid did not 
contain an insert.  
2.3.1.9  Preparation of liquid cultures of transformed colonies 
Lysogeny broth (LB) medium was prepared by adding 10 g LB broth and 7.5 g agar to 500 ml 
distilled water and autoclaving the mixture. Thereafter, 0.05 mg/ml ampicillin was added to the 
LB medium and the medium was inoculated with positive colonies detected through blue-white 
screening. A positive colony obtained in section 2.3.1.8.1 was used to inoculate 5 ml LB 
medium; positive colonies obtained in section 2.3.1.8.2 were used to inoculate 200 ml LB 
medium each. Different volumes were used for these two procedures as only a small amount of 
plasmids carrying the NeoCoV RdRp fragment was required, whereas larger amounts of pCG1 
vectors with inserts were required for the subsequent procedures. The liquid cultures were 
incubated at 37°C overnight, shaking at a speed of 225 rpm.  
2.3.1.10  Purification of plasmid DNA 
2.3.1.10.1  Purification of plasmids carrying NeoCoV RdRp fragment 
Since the transformed cells containing the cloned PCR product of interest was cultured in a 
volume less than 10 ml, the GeneJET Plasmid Miniprep kit was used to purify the plasmid DNA 
that was produced through liquid culture (section 2.3.1.9). The manufacturer‟s protocol was 
followed. Firstly, the liquid culture was centrifuged at 4 000 × g for five minutes and the 
supernatant was removed. Cells were resuspended in 250 μl resuspension solution and mixed 
by pipetting, after which 250 μl lysis solution was added to lyse cells. The contents of the tube 
were mixed by inversion and 350 μl neutralisation solution was added to the sample and mixed. 
The tube was centrifuged at 12 000 × g for five minutes, after which the supernatant was 
transferred to a provided GeneJet Spin Column in a collection tube. The column was centrifuged 
at 12 000 × g for one minute. The membrane was washed by adding 500 μl wash solution and 
centrifuging for one minute at 12 000 × g. The washing step was repeated once, after which the 
empty tube was centrifuged for one minute at 12 000 × g. The column was transferred to a 1.5 
ml microcentrifuge tube, 50 μl elution buffer was added to the column and incubated at room 
temperature for two minutes. The column was centrifuged at 12 000 × g for two minutes and the 
products were stored at -20°C after sequencing to confirm the presence of the desired insert.  
2.3.1.10.2  Purification of pCG1 vectors 
As the cells transformed with pCG1 vectors were cultured in volumes of more than 50 ml, the 
GeneJET Plasmid Midiprep kit was used to purify the plasmid DNA that was obtained through 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
liquid culture (section 2.3.1.9). The manufacturer‟s protocol was followed by dividing each liquid 
culture into aliquots of 50 ml each. Cells were harvested by centrifuging the liquid cultures at 
4 000 × g for 15 minutes and removing the supernatants. Cells were resuspended in 2 ml 
resuspension solution containing 4% v/v RNase A. Subsequently, 2 ml lysis solution was added 
to each tube and mixed by inverting, followed by addition of 2 ml neutralisation solution. After 
thoroughly mixing the contents of each tube separately, 0.5 ml endotoxin binding solution was 
added to each aliquot, mixed and incubated at room temperature for five minutes. After 
incubation, 3 ml ethanol (96% v/v) was added to each suspension and centrifuged at 4 000 × g 
for 50 minutes to remove cell debris. Supernatants were transferred to new centrifugation tubes 
and 3 ml ethanol (96% v/v) was added to each tube containing supernatant and mixed by 
inversion. Samples were loaded onto provided columns in collection tubes 5 ml at a time until 
the entire sample had been loaded. After each loading step, columns were centrifuged at 2 000 
× g for three minutes, discarding flow-through afterwards. Washing steps were performed by 
adding 4 ml washing solution I to each column and centrifuging at 3 000 × g for two minutes. 
Flow-through was discarded and the second washing step was done by adding 4 ml washing 
solution II and centrifuging at 3 000 × g for two minutes. Flow-through was discarded and the 
second washing step repeated once. Columns were then centrifuged at 3 000 × g for five 
minutes, after which columns were placed in 15 ml centrifuge tubes. Plasmid DNA was eluted by 
adding 0.35 ml elution buffer to columns, incubating tubes at room temperature for two minutes 
and centrifuging for five minutes at 4 000 × g. Products were stored at -20°C after sequencing to 
confirm the presence of the desired inserts.  
2.3.1.11  RT-qPCR 
2.3.1.11.1  Preparation of in vitro transcribed RNA standard 
Purified plasmid DNA containing the NeoCoV RdRp fragment (sections 2.3.1.7 - 2.3.1.10.1) was 
linearised by digestion with restriction enzyme EcoRI in order to prepare the circular plasmid 
DNA for in vitro transcription. A reaction mixture was prepared as described in Table 2.15.  
Table 2.15. Reaction mixture for EcoRI digestion of plasmid DNA.  
Component Volume (µl) 
Nuclease-free water to 100 
New England BioLabs 10× EcoRI Reaction Buffer  10 
Purified DNA template (2 µg)  2 μg 
New England BioLabs EcoRI (10 U/µl)  2 
Total 100 
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The reaction was incubated according to the parameters described in Table 2.16.  
Table 2.16. Incubation parameters for EcoRI digestion of plasmid DNA.  
Temperature (°C) Time (minutes) 
37 60 
65 20 
  4  ∞ 
 
The product was then purified using the MinElute PCR Purification kit according to the 
manufacturer‟s protocol. Briefly, 300 μl adsorption buffer ERC was added to the EcoRI-digested 
product. The mixture was loaded onto a provided MinElute column in a microcentrifuge tube. 
The column was centrifuged at 17 900 × g for one minute. After discarding the flow-through, 750 
μl wash buffer PE was added to the column and the column was centrifuged for one minute at 
17 900 × g. The column was centrifuged again at 17 900 × g for one minute after discarding the 
flow-through. The column was transferred to a 1.5 ml microcentrifuge tube and 10 μl elution 
buffer EB was loaded onto the column, allowing it to incubate for one minute at room 
temperature. The column was centrifuged for one minute at 17 900 × g.  
The purified product was in vitro transcribed using the TranscriptAid T7 High Yield Transcription 
kit according to the manufacturer‟s instructions. The mixture in Table 2.17 was prepared, after 
which it was incubated at 37°C for two hours.  
Table 2.17. Reaction mixture for in vitro transcription reaction.  
Component Volume (µl) 
Diethylpyrocarbonate-treated (DEPC-treated) water to 20 
5× TranscriptAid Reaction Buffer 4 
ATP/CTP/GTP/UTP mix 8 
Template DNA 1 μg 
TranscriptAid Enzyme Mix 2 
Total 20 
 
The in vitro transcribed product was digested with DNase I to remove residual DNA and obtain a 
product consisting of only RNA. This was achieved by adding 4 units of DNase I to the reaction 
and incubating it at 37°C for 15 minutes.  
The RNA was purified with the Invitrogen PureLink RNA Mini kit by following the manufacturer‟s 
protocol. The DNase I-digested product was mixed with 22 μl lysis buffer and 96% v/v ethanol 
each. This mixture was loaded onto a provided Spin Cartridge in a collection tube and 
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centrifuged at 12 000 × g for 15 seconds. The flow-through was discarded and 500 μl wash 
buffer II was added to the cartridge. The cartridge was centrifuged at 12 000 × g for 15 seconds 
and the flow-through was discarded. The washing step was repeated once. The empty cartridge 
was centrifuged for one minute at 12 000 × g. The cartridge was transferred to a 1.5 ml 
microcentrifuge tube and 30 μl nuclease-free water was added to the cartridge. The cartridge 
was incubated at room temperature and centrifuged at 12 000 × g for two minutes. The product 
was stored at -80°C.  
Purified RNA was quantified using the Qubit RNA HS Assay kit and Qubit 2.0 Fluorometer 
according to the manufacturer‟s instructions. A working solution was prepared by adding Qubit 
RNA HS Reagent to Qubit RNA HS Buffer at a ratio of 1:200. Two tubes were prepared for the 
Qubit RNA standards by adding 190 μl working solution to each tube and adding 10 μl of each 
standard (Standard #1 and Standard #2) to the corresponding tubes. The tube for sample RNA 
was prepared by adding 198 μl working solution and 2 μl sample RNA to a tube. All tubes were 
vortexed briefly and incubated at room temperature for two minutes. The option for measuring 
the concentration of RNA standards was selected on the Qubit 2.0 Fluorometer, the tube for 
Standard #1 was inserted in the instrument and a reading was taken. The step was repeated for 
Standard #2. The option for measuring the concentration of sample RNA was selected, the 
sample tube was inserted in the instrument and a reading was given and captured. The reading 
given by the instrument in ng/ml was converted to copy numbers by importing data on the 
reading and fragment size into a conversion equation on the EndMemo website (available online 
at http://www.endmemo.com/bio/dnacopynum.php). The RNA was diluted to a concentration of 
1×108 RNA copies/ml, aliquoted and stored at -80°C.  
2.3.1.11.2  Performing RT-qPCR reactions 
The SensiFAST Probe No-ROX One-Step kit was used to quantitatively measure the presence 
of NeoCoV genomic material in the supernatants removed from inoculated cell cultures and the 
bat faecal homogenate used for inoculation (refer to section 2.3.3). This was done in order to 
determine the concentration of NeoCoV in the inoculum used and whether viral replication took 
place in cell culture. The assay is able to detect a minimum of 1×105 viral RNA copies/ml.  
The mixture described in Table 2.18 was prepared for each sample. The standard in vitro 
transcribed RNA prepared in section 2.3.1.11.1 was serially diluted from 1×106 RNA copies/ml to 
1×102 RNA copies/ml, generating five standards for inclusion in each assay. Three reactions 
were prepared per standard, as well as for each of the samples, being RNA extracted from cell 
Stellenbosch University  https://scholar.sun.ac.za
42 
 
culture supernatant and RNA extracted from sample 23; two reactions were prepared for the 
negative control, which contained DEPC-treated water instead of sample RNA.  
Table 2.18. Reaction mixture for RT-qPCR reactions.  
Component Volume (µl) 
2× SensiFAST Probe No-ROX One-Step Mix 5.0 
Forward primer (10 µM) 0.4 
Reverse primer (10 µM) 0.4 
Probe (10 µM) 0.1 
Reverse Transcriptase 0.1 
RiboSafe RNase Inhibitor 0.2 
DEPC-treated water 1.8 
RNA template 2.0 
Total  10.0 
 
Thermal cycling was performed on the CFX Connect Real-Time PCR Detection System 
according to the parameters described in Table 2.19. CFX Manager Software was used to 
capture the data.  
Table 2.19. Thermal cycling parameters for RT-qPCR reactions.  
Temperature (°C) Time  
45 20 minutes  
95   2 minutes  
95   5 seconds  
60 20 seconds  
  4  ∞  
 
2.3.2  Cell culture 
Several mammalian cell lines, namely BHK-21 (G43), CaKi (camel kidney), NCK (N. capensis 
kidney), NCL (N. capensis lung), NCT (N. capensis trachea), PipNi, Vero E6 and Vero EMK 
cells, of which the species of origin were previously confirmed through cytochrome b sequence 
analysis, were cultured for this study. Pictures of these cell lines can be found in Figure D.1 in 
Addendum D. A detailed list with information on aspects such as the origins and maintenance of 
these cells is provided in Table 2.20.  
 
 
 
 ×40 cycles 
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Table 2.20. Cell lines used in this study.  
Cell line 
Country of 
origin 
Obtained from 
Organ of origin (species 
of origin) 
% foetal bovine 
serum (FBS) used 
BHK-21 
(G43) 
Germany 
Collaborators at 
Charité University 
Hospital 
Baby golden hamster 
kidney fibroblast 
(Mesocricetus auratus) 
5 
CaKi Germany 
Collaborators at 
Charité University 
Hospital 
Dromedary camel kidney 
(C. dromedarius) 
5 
NCK South Africa 
Produced in-house 
(Stellenbosch 
University) 
Cape serotine bat kidney 
(N. capensis) 
5 
NCL South Africa 
Produced in-house 
(Stellenbosch 
University) 
Cape serotine bat lung (N. 
capensis) 
10 
NCT South Africa 
Produced in-house 
(Stellenbosch 
University) 
Cape serotine bat trachea 
(N. capensis) 
10 
PipNi Germany 
Collaborators at 
Charité University 
Hospital 
Common pipistrelle bat 
kidney (P. pipistrellus) 
2 
Vero E6 USA 
Collaborators at 
Charité University 
Hospital 
African green monkey 
kidney (C. aethiops) 
5 
Vero EMK N/A 
Collaborators at 
Charité University 
Hospital 
Embryonic African green 
monkey kidney (C. 
aethiops) 
5 
 
2.3.2.1 Maintenance of cell lines 
Cells were cultured with DMEM supplemented with 1% v/v penicillin-streptomycin, 1% v/v non-
essential amino acids (NEAA), 1% v/v sodium pyruvate, 1% v/v L-glutamine and 2% - 10% v/v 
FBS, hereafter referred to as „supplemented DMEM‟.  
Cells were incubated at 37°C in a humidified incubator with 5% CO2. Cell growth was monitored 
daily using a light microscope. Cells that had not reached >90% confluence three to four days 
after passaging (i.e. transferring cells to a new cell culture vessel) were washed with PBS and 
fresh supplemented DMEM was added to the cells to maintain them until they had reached 
>90% confluence and could be passaged. Confluence refers to the percentage of a cell culture 
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vessel that is covered by cells, e.g. when half the surface of a cell culture vessel is covered with 
adherent cells, the cells are 50% confluent.  
Cryogenically frozen cell stocks were cultured and propagated as required by following a 
protocol designed to remove preservatives such as dimethyl sulfoxide (DMSO) that were used in 
the cryopreservation process. After thawing a vial containing 1 ml of cells, the contents were 
added to 4 ml PBS, gently resuspended and centrifuged at 1 000 × g for three minutes. The 
supernatant was discarded and the pellet resuspended in 5 ml PBS. The mixture was then 
centrifuged again at 1 000 × g for four minutes, after which the supernatant was removed and 
the pellet was resuspended in 5 ml supplemented DMEM. This was then added to a T25 flask 
and incubated at the aforementioned conditions.  
Cells were passaged to new flasks/plates once the cells were >90% confluent. Passaging was 
done by aspirating the media from the flask and washing the adherent cells with PBS (three 
wash steps when using 1× trypsin-ethylenediaminetetraacetic acid [trypsin-EDTA]; one wash 
step when using Accutase). Cells were then detached from the flask using 1× trypsin-EDTA or 
Accutase (depending on availability) and incubating it at 37°C with 5% CO2 for ten minutes. 
Supplemented DMEM was then added to the flask to inactivate the cell detachment medium and 
cells were seeded in a new cell culture vessel at the desired concentration. Desired 
concentrations were determined based on what purpose the newly-passaged cells would serve 
after adherence. Cells were then incubated at 37°C with 5% CO2. Table 2.21 indicates the ratios 
of reagents used for the passaging and seeding of the cells: 
Table 2.21. Reagents used for passaging and seeding of cells to culture vessels of different sizes.  
Process Reagent 
Flask size Plate size 
T25 T75 T175 6-well 12-well 
Volume (ml) 
Wash PBS 3 7 21 1/well 0.5/well 
Detachment 
1× trypsin-EDTA 1 3 7 1/well N/A 
Accutase 1 3 7 1/well N/A 
Resuspension 
Supplemented 
DMEM 
4 7 21 
Dependant on 
desired cell 
concentration 
Dependant on 
desired cell 
concentration 
Seeding (total 
volume) 
Supplemented 
DMEM 
5 18 25 2/well 1/well 
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2.3.2.2  Cell counting using a haemocytometer 
Cells that had to be seeded at specific concentrations, either for use in virus isolation 
experiments (refer to section 2.3.3) or for pseudoparticle propagation and preparation (refer to 
sections 2.3.4.1 – 2.3.4.2), were counted using a haemocytometer to determine the 
concentration of the resuspended cell suspension. A confluent monolayer of cells in a T75 flask 
was detached using 1× trypsin-EDTA or Accutase and resuspended in an appropriate amount of 
supplemented DMEM (section 2.3.2.1). The resuspended cell solution was then diluted in PBS 
at a ratio of 1:9 and mixed thoroughly. Thereafter, 10 μl of the cell suspension was added to a 
clean haemocytometer with a coverslip. Once the cell solution had spread to fill the entire 
Neubauer chamber, the section of the haemocytometer that is divided into a grid for simplified 
counting, the slide was viewed using a light microscope and all cells within each of the four sets 
of 16 squares were counted. Taking into account the dilution factor of 10 and the conversion 
factor of 104, the cell concentration was determined as follows: 
Average number of cells per large square × 105 
Thereafter, cells were seeded to plates in the desired dilution using the equation: 
C1V1 = C2V2 
where C = concentration and V = volume.  
2.3.2.3  Cryopreservation of cells 
In some cases, cell stocks were made for future use by freezing cells that had been cultured. 
This was done by detaching adherent cells once they had reached >90% confluence and 
resuspending them in the appropriate amount of DMEM (section 2.3.2.1). The resuspended cells 
were centrifuged at 3 000 × g for five minutes, after which the supernatant was removed and the 
pellet resuspended in supplemented DMEM lacking penicillin-streptomycin with 10% v/v DMSO 
added. Typically, four vials of cells were prepared in 1 ml aliquots from a T75 flask during the 
cryopreservation process. The aliquots were placed in a Mr. Frosty Freezing Container pre-
cooled to 4°C containing isopropyl alcohol, designed to prevent rapid cooling that could damage 
cells. The container was kept at -80°C overnight, after which the aliquots were transferred to a 
liquid nitrogen tank for long-term storage.  
2.3.3  Virus isolation 
Four attempts were made at isolating NeoCoV in cell culture, all using bat faecal homogenate 
obtained from sample 23 (Addendum C). Sample 23 originates from an N. capensis bat and was 
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confirmed NeoCoV-positive using the two-step screening RT-PCR and sequencing as described 
in sections 2.3.1.1 and 2.3.1.6, respectively. The isolation attempts differed mainly in inoculum 
preparation and passaging of the inoculated cells or supernatant.  
NCK cells were used for the attempted isolation of coronavirus from the bat faecal sample. The 
cells were seeded in a 6-well plate at a concentration of 2.00×105 cells/ml on the day prior to 
infection using supplemented DMEM with an FBS concentration of 5% v/v. The inoculum was 
prepared by homogenising a bat faecal pellet from sample 23 with the method described in 
section 2.3.1.1.1.  
2.3.3.1  First and second attempts at isolating NeoCoV 
For the first two attempts (attempts 1 and 2), the inocula were prepared by mixing 450 µl 
homogenate with 300 µl PBS, filtering with a 0.2 µm filter and diluting in either 1.25 ml 
supplemented DMEM with 2% v/v FBS and 1% v/v amphotericin B or 1.25 ml OptiPRO Serum-
Free Medium, respectively.  
Cell supernatant was discarded and cells were washed once with PBS. Thereafter, 2 ml of the 
inoculum was added to separate wells of the 6-well plate, after which the plate was incubated at 
37°C with 5% CO2 for one hour. The inoculum was removed and supplemented DMEM with 2% 
v/v FBS v/v and 1% v/v amphotericin B was added to each well. Cells were incubated at 37°C 
with 5% CO2.  
Cells were monitored daily for cytopathic effect (CPE) using a light microscope and 250 µl of 
supernatant was removed per well at time points 24, 48, 72 and 144 hours post-infection (h.p.i.) 
and stored at -80°C until it could be screened for evidence of replicating virus with the RT-qPCR 
assay. An additional 250 µl supplemented DMEM with 2% v/v FBS and 1% v/v amphotericin B 
was added to each well after removal of the supernatant. At 144 h.p.i. the cells were passaged 
to a new 6-well plate, after which the process of supernatant aliquot removal, storage and 
replacement took place at time points 24, 48, 72, 96 and 168 hours after passaging of the cells.  
2.3.3.2  Third and fourth attempts at isolating NeoCoV 
For the third and fourth attempts (attempts 3 and 4), filtered homogenate was added to either 
1.8 ml supplemented DMEM with 2% v/v FBS and 1% v/v amphotericin B or 1.8 ml OptiPRO 
Serum-Free Medium, respectively, at a ratio of 1:9 and added to the cells. Cells were incubated 
with the inocula for one hour at 37°C with 5% CO2. Supernatants were then removed and 
replaced with DMEM with 2% v/v FBS v/v and 1% v/v amphotericin B and incubated at 37°C 
with 5% CO2.  
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Cells were monitored daily for CPE and the removal, storage and replacement of supernatant 
was done as described for attempts 1 and 2 (section 2.3.3.1) at time points 24, 48, 72, 92 and 
144 h.p.i. At 144 h.p.i., blind passaging was done by transferring 200 µl of the supernatant into a 
new cell culture vessel. Blind passaging refers to the process of transferring supernatant that 
might be virus-positive, but which has not been confirmed virus-positive through any molecular 
tests, to fresh cells. Supernatant was removed, stored and replaced at time points 24 and 48 
hours after passaging. At time point 48 hours after virus passage, 500 µl of supernatant was 
removed and stored at -80°C. Subsequently, 200 μl of this stored supernatant was used to 
inoculate new cells in 1.8 ml supplemented DMEM. Supernatant (250 μl) was removed 24 h.p.i. 
and stored at -80°C.  
2.3.4  Pseudoparticle production and infection 
2.3.4.1  Propagation of recombinant VSV for pseudotyping 
Genetically modified VSV-G-trans-complemented VSV particles without the ability to replicate 
(hereafter referred to as VSV*ΔG-Luc + VSV-G) were produced for future use in preparing 
pseudoparticles that express different surface proteins according to a method described by 
Hoffmann (2017). BHK-21 (G43) cells, which are able to be induced to express VSV-G for trans-
complementation to take place (Hanika et al., 2005; Hoffmann, 2017), were seeded in two T75 
flasks at a concentration of 1.50×105 cells/ml to be 70% to 80% confluent within 24 hours of 
seeding. The supernatant was removed and cells were washed once with PBS. Subsequently, 
15 ml supplemented DMEM with 10-8 M mifepristone was added to cells to induce the expression 
of VSV-G, after which they were incubated at 37°C with 5% CO2 for six hours. The cell 
supernatant was then discarded and cells were washed once with PBS. A volume of 10 ml 
supplemented DMEM containing VSV*ΔG-Luc + VSV-G (provided by collaborators from Charité 
University Hospital) at a ratio of 1:999 was added to the cells, after which they were incubated at 
37°C with 5% CO2 for one hour. The cell supernatant was then discarded. Cells were washed 
thrice with PBS and 15 ml supplemented DMEM with 10-8 M mifepristone was added to the cells, 
which were then incubated overnight at 37°C with 5% CO2.  
Cells were monitored for CPE under a light microscope 18 to 20 h.p.i. Once >50% of cells 
showed signs of CPE, cell culture supernatant was removed from flasks, added to centrifugation 
tubes and centrifuged at 1 000 × g at 4°C for ten minutes to remove cell debris present in the 
supernatant. After centrifugation, the supernatant was aliquoted into new tubes and stored at -
80°C.  
Stellenbosch University  https://scholar.sun.ac.za
48 
 
2.3.4.2  Preparation of pseudoparticles expressing various surface proteins 
Pseudoparticles expressing MERS-CoV- (ppMERS-S), NeoCoV- (ppNCV-S) and SARS-CoV- 
(ppSARS-S) S proteins were produced in order to determine whether MERS-CoV, NeoCoV and 
SARS-CoV can infect a selection of different cell lines selected for this study. Pseudoparticles 
expressing no foreign surface proteins (ppEV) and pseudoparticles expressing VSV-G (ppVSV-
G) were also produced to act as negative and positive controls, respectively, according to the 
method described by Hoffmann (2017).  
2.3.4.2.1  Transfection of cells 
BHK-21 (G43) cells were seeded into five T25 flasks at a concentration of 105 cells/ml to reach 
~70% confluence at the time of transfection (~24 hours after seeding). Cell supernatant was 
discarded and cells were washed thrice with PBS. Thereafter, 4.5 ml supplemented DMEM with 
an FBS concentration of 3% v/v was added to each flask.  
Five individual transfection solutions were prepared, each containing 500 µl DMEM and 12 µl 
Invitrogen Lipofectamine 2000. Subsequently, 6 µg plasmid DNA, either pCG1, pCG1-VSV-G, 
pCG1-MERS-S, pCG1-NCV-S or pCG1-SARS-S (Table 2.3), was added to one of the mixtures 
and incubated at room temperature for 40 minutes.  
The transfection solutions were added to the respective T25 flasks and incubated at 37°C with 
5% CO2 for six hours. Cell supernatant was then discarded, cells were washed twice with PBS 
and supplemented DMEM was added to each flask. Cells were incubated at 37°C with 5% CO2 
overnight.  
2.3.4.2.2  Infection with VSV*ΔG-Luc + VSV-G 
Cell supernatant was discarded following overnight incubation and cells were washed twice with 
PBS. Subsequently, 3.5 ml DMEM containing a 1:9 ratio of VSV*ΔG-Luc + VSV-G (section 
2.3.4.1) to DMEM was added to each transfected T25 flask (VSV*ΔG-Luc + VSV-G needed to 
be applied at a multiplicity of infection [MOI] of at least 3; i.e. three particles needed to be added 
for every cell present in the sample). The flasks were incubated under slight agitation at room 
temperature for half an hour, after which it was incubated at 37°C with 5% CO2 for 45 minutes. 
After incubation, cell supernatant was discarded and cells were washed eight times with PBS to 
remove any residual VSV*ΔG-Luc + VSV-G. After washing, 5 ml supplemented DMEM was 
added to each flask. The flasks were then incubated overnight at 37°C with 5% CO2.  
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After overnight incubation of ±18 hours, cell supernatants were transferred to separate 
centrifugal tubes and centrifuged at 1 000 × g at 4°C for ten minutes to pellet cell debris. The 
supernatants containing pseudoparticles were then transferred to sterile tubes which were 
stored at 4°C if used within two weeks or at -80°C for long-term storage.  
2.3.4.3  Determination of pseudoparticle titres by flow cytometry 
The titre of the VSV*ΔG-Luc + VSV-G stock and that of the individual pseudoparticles were 
determined by inoculating Vero E6 cells with the particles generated as described in section 
2.3.4.4.1. This was achieved by seeding Vero E6 cells onto 6-well plates at a concentration of 
2×105 cells/ml to reach ~70% confluence 24 hours after seeding. A 10-3 dilution of VSV*ΔG-Luc 
+ VSV-G stock was prepared in DMEM; 1 ml dilutions of a 1:9 ratio of pseudoparticles to DMEM 
were prepared for each of the different pseudotypes (ppVSV-G. ppEV, ppMERS-S, ppNCV-S 
and ppSARS-S). Infection was performed in triplicate by adding 1 ml of each dilution to three 
separate wells. Next, the plates were agitated at 80 rpm at room temperate for half an hour, then 
incubated at 37°C with 5% CO2 for 45 minutes. Thereafter, the supernatants were aspirated and 
supplemented DMEM was added to the cells before incubating at 37°C with 5% CO2 for 24 
hours.  
Cells were subsequently fixed for flow cytometry which was performed as described in section 
2.3.4.4.3. The results were analysed with FlowJo version 10.4.2 software, after which the total 
number of infected cells were determined by multiplying the percentage of infected cells with the 
number of cells in each corresponding sample, which were counted using the method in section 
2.3.2.2. An average was calculated from this data using the formula below. This average was 
used to determine the number of recombinant VSV particles or newly generated pseudotyped 
viruses per ml by taking into account the dilution factors for each.  
Cells/sample × % GFP expressing cells detected = GFP expressing cells in sample 
2.3.4.4  Infection and analysis of pseudoparticle infections 
2.3.4.4.1  Infection of various cell lines with pseudoparticles 
Cell lines of various origins (table 2.20) were infected with the generated pseudoparticles to 
investigate the possible host range of NeoCoV and how it compares with that of MERS-CoV and 
SARS-CoV. NCK and Vero E6 cells were infected using the protocol that allows for analysis by 
fluorescence microscopy; CaKi, NCK, NCL, NCT, PipNi, Vero E6 and Vero EMK cells were 
infected according to the method that is used for analysis by flow cytometry as explained in the 
below sections.  
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Infection of cells with pseudoparticles was achieved by seeding the required cells in a 12-well 
plate (fluorescence microscopy [refer to section 2.3.4.4.2]) or a 6-well plate (flow cytometry [refer 
to section 2.3.4.4.3]) at a concentration of 2×105 cells/ml that led to 70% to 80% confluence at 
the time of infection (±24 hours after seeding). Cells were seeded onto coverslips with a 16 mm 
diameter for fluorescence microscopy and were seeded directly onto 6-well plates for flow 
cytometry purposes. Cell supernatant was discarded and cells were washed once with PBS 
before adding pseudoparticle stock in 2 ml OptiPRO Serum-Free Medium (fluorescence 
microscopy) or 1 ml DMEM (flow cytometry) at a ratio of 1:9 to each well. One well of cells to be 
analysed by flow cytometry remained uninfected for each cell line in order to act as a negative 
control. Infections were performed in duplicate for samples to be used in fluorescence 
microscopy and in triplicate for samples analysed by flow cytometry. Cells were agitated at 80 
rpm at room temperature for half an hour; thereafter incubated at 37°C with 5% CO2 for 45 
minutes. The supernatant was removed and cells were washed once with PBS. Supplemented 
DMEM was added to the cells and incubated at 37°C with 5% CO2 for 24 hours, after which they 
were prepared for analysis by fluorescence microscopy or flow cytometry.  
2.3.4.4.2  Preparation of cells for fluorescence microscopy and analysis 
NCK and Vero E6 cells infected with pseudoparticles (section 2.3.4.4.1) were analysed by 
fluorescence microscopy to determine if GFP expression indicating positive pseudoparticle 
infection had occurred. To achieve this, cells had to be fixed, stained and mounted before being 
viewed on a fluorescence microscope.  
The cell supernatant of infected cells was removed after 24 hours of incubation and cells were 
washed thrice with PBS. Cells were fixed onto coverslips by incubating at room temperature in 
4% v/v formaldehyde in 1× PBS for 20 minutes. Thereafter, the supernatant was removed and 
cells were washed twice with PBS. Cells were stained by adding 300 µl 4‟,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) at a concentration of 300 nM to each coverslip and 
incubating in the dark for five minutes. The DAPI was removed, cells were washed twice with 
PBS and once with distilled water.  
Coverslips were mounted using ProLong Gold antifade reagent. Coverslips with fixed and 
stained cells were removed from the wells, dabbed on paper to remove excess water and placed 
inverted on a drop of mounting media on a microscope slide. The mounted samples were 
allowed to dry in the dark at 4°C overnight, after which the edges of the coverslips were sealed 
with clear nail polish. The slides were analysed by fluorescence microscopy with an Eclipse Ci 
microscope, making use of the DAPI and GFP filters. Slides were photographed using Sperm 
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Class Analyzer software. The total number of cells and GFP expressing cells were determined 
by counting the visualised cells by eye. Slides were stored at 4°C when not in use.  
2.3.4.4.3  Preparation of cells for flow cytometry and analysis 
CaKi, NCK, NCL, NCT, PipNi, Vero E6 and Vero EMK cells infected with pseudoparticles 
according to the method described for analysis by flow cytometry, along with a well of uninfected 
cells, were prepared for flow cytometry, which was used to measure GFP expression by cells, 
indicating infection by pseudoparticles. Briefly, cells were fixed by washing cells once with PBS, 
incubating with Accutase and incubating at 37°C for ten minutes. Detached cells were then 
transferred to 15 ml centrifuge tubes and centrifuged at 4 000 × g for three minutes, after which 
cells were washed twice in 1 ml PBS and centrifuged at 4 000 × g for three minutes each time. 
Thereafter, 4% v/v formaldehyde in 1× PBS was added to the cells and incubated at 4°C for ten 
minutes. Cells were then centrifuged at 4 000 × g for three minutes, after which the supernatant 
was removed and cells were resuspended in 250 μl PBS. The cell suspensions were stored at 
4°C prior to performing flow cytometry.  
The data on the percentage of GFP expressing cells were acquired using the BD FACSCanto II 
flow cytometer along with BD FACSDiva software. Cytometer Setup and Tracking beads were 
processed on the machine daily to ensure that data were standardised. The uninfected cell 
sample of each cell line was processed first to determine the robust standard deviation value of 
each cell line, after which a gate was created to separate uninfected cells from ones expressing 
GFP when subsequently running the infected cells. Data were acquired on a total of 1×104 
events per sample.  
The results were analysed with FlowJo version 10.4.2 , after which the total number of infected 
cells was determined by multiplying the percentage of infected cells with the number of cells in 
each corresponding sample. An average was calculated from this data, which was used to 
determine the number of pseudoparticle-infected cells for each cell line and pseudotyped virus.  
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CHAPTER 3 
3  Results 
3.1  Screening bat faecal samples for NeoCoV 
3.1.1  PCR of bat faecal samples 1 to 30 
In order to determine whether any of the bat faecal samples were NeoCoV positive, samples 
were screened with a PCR assay targeting different regions in the RdRp region of the 
coronavirus genome using four different primer sets, as described in section 2.3.1.1.4. The 
products of the screening PCR were visualised after agarose gel electrophoresis (section 
2.3.1.3).  
Overall, 12 of the 30 samples screened (40%) yielded fragments of the expected sizes. 
Fragments of the correct sizes were obtained for samples 12, 16, 17, 18, 19 and 20 using PCR 
Gr1Sp (Figure 3.1 A), for samples 17, 18, 19, 23 and 25 using PCR RGU_2c (Figure 3.1 B), for 
samples 16, 17 and 19 using PCR SP3080 F1 (Figure 3.1 C), and for samples 2, 9, 12, 14, 17, 
18, 19 and 22 using PCR SP3374 F3 (Figure 3.1 D).  
 
Figure 3.1. Screening for coronaviruses using four different primer sets. A) PCR Gr1Sp; fragment 
size = 974 bp. B) PCR RGU_2c; fragment size = 974 bp. C) PCR SP3080 F1; fragment size = 974 bp. D) 
PCR SP3374 F3; fragment size = 682. 1kb = GeneRuler 1kb DNA Ladder; PC = positive control; NC = 
negative control.  
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3.1.2  Sequencing 
Amplified PCR products of the desired sizes from section 3.1.1 were purified and sequenced as 
described in sections 2.3.1.4 and 2.3.1.6, respectively, using the BigDye Terminator v3.1 Cycle 
Sequencing kit with the corresponding primers. Sequences were analysed using Geneious R10 
bioinformatics software and NCBI BLAST online tool was utilised to determine genetic similarity 
to other coronavirus sequences available in the database. BLAST results revealed four alpha-, 
four beta- and four unclassified coronavirus sequences. For the purposes of this study, only 
sample 23 generated a 974 bp fragment by PCR RGU_2c that aligned to NeoCoV (GenBank 
accession number: KC869678) with 100% similarity. Sample 23 was therefore regarded as 
positive for NeoCoV.  
3.2  Attempted isolation of NeoCoV in cell culture 
3.2.1  Inoculation, passaging and monitoring for CPE 
Isolation of NeoCoV in cell culture was attempted four times on NCK cells. Sample 23, of which 
the partial RdRp fragment shared 100% homology with that of the NeoCoV strain originally 
discovered by Ithete et al. (2013) (GenBank accession number: KC869678), was selected as the 
sample to be used for virus isolation on NCK cells in culture (section 2.3.3).  
NCK cells were inoculated with bat faecal homogenate and monitored for signs of CPE. For 
attempts 1 and 2, cells were monitored visually at 24, 48, 72 and 144 hours post-inoculation with 
bat faecal homogenate and 24, 48, 72, 96 and 168 hours after cell passaging. For attempts 3 
and 4, cells were monitored for CPE at 24, 48, 72, 92 and 144 hours post-inoculation with bat 
faecal homogenate, 24 and 48 hours after the first supernatant passage and 24 hours after the 
second virus passage. No discernible CPE was seen at any of the time points for any attempt. 
An RT-qPCR was done in order to assess virus growth in the case that any virus possibly 
isolated was non-lytic. 
3.2.2  Analysis of NeoCoV replication by RT-qPCR 
3.2.2.1  Generation of RT-qPCR standard 
An in vitro transcribed RNA standard to be used as a standard with a known viral RNA 
concentration was generated for the RT-qPCR assay (section 2.3.1.11.1). This was done in 
order to quantify the viral RNA in samples with unknown concentrations. The fragment of the 
RdRp region of the NeoCoV genome generated by PCR RGU_2c for sample 23 was cloned into 
a pTZ57R/T vector. Plasmid DNA was sequenced after purification. After confirmation of the 
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presence of the fragment using the NCBI BLAST online tool, the plasmid was linearised and in 
vitro transcribed.  
3.2.2.2  RT-qPCR for the detection of NeoCoV 
The SensiFAST Probe No-ROX One-Step kit was used for RT-qPCR reactions that detected the 
presence of the NeoCoV RdRp region with a limit of detection of 105 viral RNA copies/ml 
(section 2.3.1.11.2). The assay was used to detect the presence of NeoCoV RNA in the 
supernatants removed from inoculated cell cultures and the bat faecal homogenate used for 
inoculation.  
According to RT-qPCR analysis, the homogenate used for inoculation contained 7.72×105 viral 
RNA copies/ml. Furthermore, RT-qPCR analysis of the RNA extracted from the supernatants 
removed at each time point for revealed that no NeoCoV viral RNA was present in any of the 
extracted supernatants of attempts 1, 2 or 4. For attempt 3, 1.28×105 viral RNA copies/ml were 
detected 48 h.p.i. in the sample inoculated with DMEM containing NeoCoV-positive 
homogenate.  
3.3  Pseudoparticle infections 
3.3.1  Generation of pseudoparticles 
3.3.1.1  Propagation of VSV*ΔG-Luc + VSV-G for pseudotyping 
A stock of replication-incompetent, VSV-G-trans-complemented VSV (VSV*ΔG-Luc + VSV-G) 
was propagated according to the method described in section 2.3.4.1 to be used in the 
generation of pseudoparticles expressing heterologous proteins. This was done by infecting 
BHK-21 (G43) cells with a stock and harvesting the supernatant containing newly-generated 
VSV*ΔG-Luc + VSV-G.  
The titre of this stock was determined by infecting Vero E6 with the stock of pseudotyped VSV 
particles as described in section 2.3.4.3. Flow cytometry was performed on the cells as 
described in section 2.3.4.4.3 to detect GFP expression.  
The average titre of the VSV*ΔG-Luc + VSV-G stock was determined to be ~1.10×107 
particles/ml.  
3.3.1.2  Generation of VSV-based coronavirus pseudoparticles 
Pseudoparticles expressing the VSV-G (ppVSV-G), MERS-CoV S (ppMERS-S), NeoCoV S 
(ppNCV-S) and SARS-CoV (ppSARS-S) proteins, as well as pseudoparticles that do not express 
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any heterologous proteins, namely ppEV, were generated as described in section 2.3.4.2. 
Briefly, BHK-21 (G43) cells were transfected with plasmids carrying the genes of interest and 
infected with VSV*ΔG-Luc + VSV-G, after which supernatants containing pseudotyped viruses 
were harvested and stored until use.  
The titres of these pseudotyped viruses were determined by infecting Vero E6 cells with the 
pseudoparticles as described in section 2.3.4.3 and performing flow cytometry to measure GFP 
expression (section 2.3.4.4.3). The cells in each sample were counted (section 2.3.2.2) and 
pseudoparticle titres were calculated using the formula in section 2.3.4.3. The average titre 
calculated for each pseudotype is shown in Table 3.1.  
Table 3.1. Titres of coronavirus and control pseudotypes.  
Pseudotyped virus Number of pseudoparticles/ml 
ppVSV-G 6.36×10
5
 
ppEV 1.11×10
4
 
ppMERS-S 5.90×10
5
 
ppNCV-S 5.70×10
5
 
ppSARS-S 5.75×10
5
 
3.3.2  Infection of various mammalian cell lines using coronavirus 
pseudoparticles 
3.3.2.1  Analysis of infection using fluorescence microscopy 
NCK and Vero E6 cells were infected with ppEV, ppVSV-G, ppMERS-S, ppNCV-S and ppSARS-
S as described in section 2.3.4.4.1. The expression of GFP was measured through fluorescence 
microscopy, as described in section 2.3.4.4.2, and used to infer the number of pseudoparticle 
infections. This was achieved by counting the total number of cells on the slide using the DAPI 
filter of the microscope, followed by counting the number of GFP expressing cells using the GFP 
filter and calculating the percentage of GFP expressing cells. A representative picture of the 
different fields visualised through fluorescence microscopy can be seen in Figure 3.2. The 
images generated for all fields captured for infection of both cell lines resulted in similar images, 
therefore only a representative picture is shown.  
Stellenbosch University  https://scholar.sun.ac.za
56 
 
 
Figure 3.2. Fluorescence imaging of pseudoparticle infections. Microscopic fields were imaged at 40ˣ 
magnification after infection of Vero E6 cells with pseudoparticles. Cells were stained with DAPI 24 h.p.i. 
The blue regions represent nuclear staining of all cells by DAPI fluorescent dye. The green regions 
represent cells expressing GFP due to pseudoparticle infection. Bar = 100 µm.  
3.3.2.2  Analysis of infection using flow cytometry 
Seven cell lines, namely CaKi, NCK, NCL, NCT, PipNi, Vero E6 and Vero EMK cells were 
infected with ppEV, ppVSV-G, ppMERS-S, ppNCV-S and ppSARS-S according to the protocol 
described in section 2.3.4.4.1. The expression of GFP was measured using flow cytometry 
(section 2.3.4.4.3). A representative image of flow cytometry results can be seen in Figure 3.3. 
The flow cytometry data generated was expressed in percentages and all produced similar 
graphs when visually expressed, as shown in Figure 3.3; therefore, only one representative 
image is shown here. All graphs generated from flow cytometry data for the cell lines can be 
found in Figure E.1 in Addendum E. The subsequent graphs in this section provide more 
information on the infections based on the number of cells infected with each pseudotyped virus.  
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Figure 3.3. GFP expression measured through flow cytometry in NCK cells. Each graph shows the 
GFP measured per pseudoparticle, which was done in triplicate, therefore yielding three graphs per 
pseudoparticle. The first peak for each sample shows the cells that do not express GFP, with the smaller 
peaks (if present) showing the number of GFP expressing cells. The number of events is indicated on the 
y-axis, while the GFP fluorescence intensity is indicated on the x-axis. 
Cells in each sample were counted as described in section 2.3.2.2 and the number of infected 
cells for each of the pseudoparticles in each cell line was calculated using the formula in section 
2.3.4.3. Since infections were performed in triplicate for each different pseudotyped virus for 
each cell line, an average was determined for each.  
3.3.2.2.1  Infection of NCK cells with coronavirus pseudoparticles 
As can be seen in Figure 3.4, ppNCV resulted in the highest number of infected cells of the 
three pseudoparticles of interest when infecting NCK cells, with an average number of infections 
at 7.60×104. The ppMERS-S-infection yielded the second highest number of infected cells, with 
an average of 5.05×104 infections. Infection with ppSARS-S resulted in the lowest number of 
GFP expressing cells, with an average number of 4.60×104 GFP expressing cells.  
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Figure 3.4. Infection of NCK cells with coronavirus pseudoparticles. Bars show the average number 
of infected cells for each pseudoparticle infection as determined by flow cytometry.  
3.3.2.2.2  Infection of PipNi cells with coronavirus pseudoparticles 
For infection of PipNi cells, it was found that ppSARS-S had the highest infection level of the 
three viruses being investigated (Figure 3.5). It had an average of 6.54×102 infected cells, with 
ppMERS-S and ppNCV-S having an average number of 4.71×102 and 3.62×102 infected cells, 
respectively.  
 
Figure 3.5. Infection of PipNi cells with coronavirus pseudoparticles. Bars show the average number 
of infected cells for each pseudoparticle infection as determined by flow cytometry.  
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3.3.2.2.3  Infection of Vero E6 cells with coronavirus pseudoparticles 
Figure 3.6 shows the number of Vero E6 cells infected by each of the different pseudoparticles. 
The results are very similar for ppMERS-S, ppNCV-S and ppSARS-S, with average numbers of 
5.91×104, 5.70×104 and 5.75×104 infected cells, respectively.  
 
Figure 3.6. Infection of Vero E6 cells with coronavirus pseudoparticles. Bars show the average 
number of infected cells for each pseudoparticle infection as determined by flow cytometry.  
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3.3.2.2.4  Infection of Vero EMK cells with coronavirus pseudoparticles 
For infection of Vero EMK cells with the three pseudoparticles of interest, ppNCV-S and 
ppSARS-S showed similar levels of infection, as can be seen in Figure 3.7. The number of 
ppMERS-S-infected cells was lower, at an average number of infections of 2.20×104, which is 
only 48% of the number of ppNCV-S-infected cells, and 46% of ppSARS-S-infected cells.  
 
Figure 3.7. Infection of Vero EMK cells with coronavirus pseudoparticles. Bars show the average 
number of infected cells for each pseudoparticle infection as determined by flow cytometry.  
3.3.2.2.5  Infection of CaKi, NCL and NCT cells with coronavirus pseudoparticles 
Results were inconclusive for the infection of the CaKi, NCL and NCT cells. The percentages of 
GFP expressing cells obtained through flow cytometry were either very low and/or varied widely 
between the triplicates. The results of the infections of these cell lines were thus excluded from 
further analysis.  
3.4  Screening cell cultures for Mycoplasma contamination 
In order to determine whether the cell cultures used for the isolation of NeoCoV, propagation 
and preparation of pseudoparticles, and infection with pseudoparticles were not contaminated 
with Mycoplasma, the supernatants of the cell cultures were screened for Mycoplasma 
contamination with the protocol described in section 2.3.1.2. PCR products were visualised on 
agarose gels after electrophoresis. All cultures were negative for Mycoplasma contamination, 
except for the CaKi cells, for which a product of 500 bp was amplified and visualised through 
agarose gel electrophoresis. This fragment was purified and sequenced using the BigDye 
Terminator v3.1 Cycle Sequencing kit with the reverse Mycoplasma screening primers. After 
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analysing with Geneious R10 bioinformatics software, sequences were put through the BLAST 
online tool by NCBI and it was found that the amplified product aligned to M. hyorhinis (GenBank 
accession number: CP003231.1).  
  
Stellenbosch University  https://scholar.sun.ac.za
62 
 
CHAPTER 4 
4  Discussion 
4.1  Detection and identification of coronaviruses 
Thirty bat faecal samples were screened for the presence of coronaviruses. A two-step RT-PCR 
using four different primer sets was used in order to detect NeoCoV in samples, if present. Even 
though primers for PCRs Gr1Sp, SP3080 F1 and SP3374 F3 were initially designed for the 
detection of alphacoronaviruses and SARS-related coronaviruses, they have been found to 
successfully detect MERS-related coronaviruses if they are present in high titres (Cronjé, 2017), 
therefore, the aforementioned PCRs were used in this study for the detection of the MERS-
related NeoCoV.  
Of the 30 samples tested, 40% were positive for coronaviruses. Of the 12 positive samples, four 
belonged to the genus alphacoronavirus, four to betacoronavirus, and four were unclassified 
coronaviruses. This high proportion of positives correlates with the literature as coronaviruses 
have been found to be highly prevalent in bat populations (Masters, 2006; Smith & Denison, 
2012; Ithete, 2013; Ithete et al., 2013; Coleman & Frieman, 2014; Corman et al., 2014, Cronjé, 
2017; Banerjee et al., 2018).  
Since NeoCoV was originally found in an N. capensis bat (Ithete, 2013; Ithete et al., 2013; 
Corman et al., 2014), it is known that the virus is able to infect N. capensis bats and that this 
virus might be present in other individuals of this bat species, as found by Cronjé (2017). It is 
therefore conceivable that NeoCoV was detected in sample 23, which originates from an N. 
capensis bat, using PCR RGU_2c. With sample 23 having the highest genetic similarity to 
NeoCoV of the sequences obtained from samples that were screened and the virus having a 
high titre as determined by RT-qPCR, it was chosen to be used in virus culturing and isolation 
attempts.  
4.2  Failure to isolate NeoCoV in cell culture 
Studying viruses through isolation in cell culture plays an important part in the characterisation of 
viruses (Lednicky & Wyatt, 2012; Dijkman et al., 2013; Hoffmann et al., 2013; Banerjee et al., 
2018), as it allows for the monitoring of cellular responses to viral infection, as well as the 
investigation of viral replication. Moreover, novel viruses have to be studied in cell culture in 
order to observe their pathogenicity and assess the possibility of spillover events that can occur 
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(Eckerle et al., 2014). Since NeoCoV is highly related to MERS-CoV, it is important to 
investigate the behaviour of NeoCoV in cell culture.  
In this study, four attempts were made at isolating NeoCoV. NCK cells were inoculated with 
inocula containing ~3.47×105 viral RNA copies in attempts 1 (inoculum prepared with DMEM) 
and 2 (inoculum prepared with OptiPRO Serum-Free Medium), and ~1.54×105 viral RNA copies 
for attempts 3 (inoculum prepared with DMEM) and 4 (inoculum prepared with OptiPRO Serum-
Free Medium), respectively. Supernatant was removed from cell cultures at 24, 48, 72 and 144 
h.p.i. and 24, 48, 72, 96 and 168 hours after cell passaging for the first two attempts. For 
attempts 3 and 4, supernatant was removed at 24, 48, 72, 92 and 144 h.p.i, 24 and 48 hours 
after the first virus passage and 24 hours after the second virus passage. An RT-qPCR sensitive 
enough to detect 105 viral RNA copies/ml was used to monitor the supernatant from inoculated 
cell cultures. During the first, second and fourth attempts, no viral RNA was detected at any of 
the time points. During attempt 3, ~1,28×105 copies of viral RNA/ml was detected 48 h.p.i. in the 
supernatant from the cells inoculated with the DMEM-homogenate mixture, but no viral RNA 
copies were detected at any of the other time points.  
Isolation of bat coronavirus has been attempted repeatedly (Lau et al., 2005; Poon et al., 2005; 
Chu et al., 2006; Tang et al., 2006; Woo et al., 2007; Gloza-Rausch et al., 2008; Drexler et al., 
2010; Gouilh et al., 2011; Moreno et al., 2017; Lau et al., 2018b), but has only been successful 
in two cases in which SARS-CoV-like bat coronaviruses were isolated using Vero E6 cells and 
transgenic HeLa cells bearing the ACE2 receptors, respectively (Ge et al., 2013; Yang et al., 
2016). Cells lines such as Vero E6 are known to be susceptible to many different viruses and 
have often been used in virus isolation attempts (Govorkova et al., 1996; Lednicky & Wyatt, 
2012; Ge et al., 2013; Wei et al., 2017; Banerjee et al., 2018). However, numerous attempts 
utilising Vero E6 and other commercially-available cell lines for samples originating from bats 
failed (Lau et al., 2005; Poon et al., 2005; Chu et al., 2006; Tang et al., 2006; Woo et al., 2007; 
Gloza-Rausch et al., 2008; Drexler et al., 2010; Gouilh et al., 2011; Moreno et al., 2017; Lau et 
al., 2018b), as these cell lines do not provide conditions that are suitable for the proliferation of 
the virus it attempts to isolate, such as expression of receptors necessary for binding and entry 
(Eckerle et al., 2014). Failure to isolate coronavirus from bat samples may therefore be, at least 
in part, due to a lack of availability of bat-derived cell lines (Crameri et al., 2009; Eckerle et al., 
2014; Banerjee et al., 2018).  
In this study, a host-derived cell line, namely NCK, which was derived from N. capensis kidneys, 
was used in attempts to isolate NeoCoV. This and other N. capensis-derived cell lines such as 
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NCL and NCT developed from N. capensis lungs and tracheas, respectively, were developed for 
the purpose of isolating NeoCoV. Using host-derived cell lines is the most direct method with 
which to mimic virus-host interactions in a laboratory setting. In addition, supernatant was 
passaged in order to accommodate for virus adaptations to cell culture (Borucki et al., 2013). 
However, no viral replication could be demonstrated. Therefore, a method to isolate NeoCoV 
remains to be discovered. This confirms the complexity of the issue of bat virus isolation 
commonly reported in the literature (Lau et al., 2005; Poon et al., 2005; Chu et al., 2006; Tang et 
al., 2006; Woo et al., 2007; Gloza-Rausch et al., 2008; Drexler et al., 2010; Gouilh et al., 2011; 
Moreno et al., 2017; Banerjee et al., 2018; Lau et al., 2018b).  
One explanation for the detection of a low level of viral RNA copies at one time point only in one 
of four attempts is that viral particles from the inoculum, whether viable or not, did not adsorb 
and enter the cells and may also not have been removed during the washing step following 
inoculation and adsorption. Hence the RNA detected 48 h.p.i. may have been a result of residual 
virus particles which failed to produce culture in vitro or residual RNA from lysed virus particles.  
A lack of sufficient contact at the virus-cell interface may be a reason these isolation attempts 
did not yield a viable virus culture. There is a possibility that the virus did not enter the cells 
during the adsorption phase of infection, as adsorption time affects the success of viral infection 
in coronaviruses (Richards & Weinheimer, 1985; Schwegmann-Wessels et al., 2011). According 
to Richards and Weinheimer (1985), static adsorption (i.e. virus incubation without agitation) 
leads to a decreased success of infection, which could be an explanation for the failure of these 
four attempts since the incubation for all four attempts did not involve agitation. Similarly, as the 
isolation procedure is done largely by trial and error, and assuming that viral entry did occur, it is 
possible that amounts of virus passaged serially were insufficient to elicit CPE or a sustained 
infection, and was therefore undetectable.  
Maintaining the cold chain is a vital part of the sampling process, as disruption of the cold chain 
could lead to a loss of viable viral material in samples (Nasci et al., 2002; USAID, 2013). Failure 
to isolate NeoCoV from the sample could be the result of virus degradation due to the disruption 
of the cold chain, leading to RT-qPCR-detectable viral RNA fragments but degraded viral 
particles in samples. Considering that the samples had to be transported from the field to the 
laboratory, where it needed to be processed before cryopreservation, as well as freeze-thawing 
when using the same sample for multiple assays, there are many different stages at which the 
cold chain could have been interrupted. The sample in question had been stored at -80°C for 
four months before use, during which time it had been freeze-thawed at least three times before 
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using the sample for inoculation. Interruption of the cold chain is therefore a plausible reason for 
the failure to isolate NeoCoV.  
Furthermore, innate bat immune mechanisms are known to be an obstruction in isolation of 
coronaviruses, even in vitro (Eckerle et al., 2014; Banerjee et al., 2018). As attempts at virus 
isolation were performed on bat-derived cells, it is possible that infection by NeoCoV particles 
present in inocula were inhibited by innate immune mechanisms.  
4.3  Pseudoparticle generation and infection 
A VSV pseudotyped system that expresses GFP upon infection was used to express 
heterologous proteins in this study. This system, VSV*∆G-Luc + VSV-G, was propagated on 
BHK-21 (G43) cells (inducible to express VSV-G) in order to obtain more particles to be used in 
the preparation of pseudoparticles that express foreign proteins. Vero E6 cells were infected 
with VSV*∆G-Luc + VSV-G and flow cytometry, detecting GFP expression, was subsequently 
performed in order to determine the titre of the stock.  
Vero E6 cells were successfully infected with VSV*∆G-Luc + VSV-G stock, resulting in a titre of 
1.10×107 particles/ml. The titre of pseudoparticles generated was sufficient for use in the 
preparation of the different pseudotyped viruses, as infecting at an MOI of 3 or more has been 
found to yield high pseudoparticle titres (Hoffmann, 2017).  
The VSV*∆G-Luc + VSV-G system was used to infect BHK-21 (G43) cells that were transfected 
with vectors to express the S proteins of MERS-CoV, NeoCoV and SARS-CoV, as well as VSV-
G (positive control) and no surface proteins (negative control). Infection of transfected cells with 
VSV*∆G-Luc + VSV-G resulted in the formation of pseudoparticles expressing MERS-CoV, 
NeoCoV and SARS-CoV S proteins, VSV-G and no proteins (ppMERS-S, ppNCV-S, ppSARS-S, 
ppVSV-G and ppEV, respectively). Pseudoparticle titres were determined by infecting Vero E6 
cells and performing flow cytometry to measure GFP expression, a method previously used to 
determine GFP expressing cells by infection with VSV*∆G (Coil & Miller, 2004).  
Titres of ppVSV-G, ppMERS-S, ppNCV-S and ppSARS-S were similar, indicating that 
transfection and budding took place in equal measures for these pseudoparticles during 
preparation. The ppVSV-G yielded a slightly higher titre than the three pseudotyped viruses of 
interest, which is anticipated, as it is likely that VSV incorporates its authentic glycoprotein, VSV-
G, with the highest efficiency. The titre calculated for ppEV does not truly represent the number 
of ppEV particles in samples, but rather the GFP expression for infections with the VSV*∆G-Luc 
+ VSV-G used in the preparation of pseudotyped viruses. This „titre‟ can be used as the 
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baseline; thus, if any of the other pseudotypes infect the same number of cells or less than ppEV 
for any given infection experiment, it is probably the result of infection by VSV*∆G-Luc + VSV-G 
and not of the specific pseudotype (Giroud et al., 2017; Li et al., 2017).  
For pseudoparticle generation, it is required to ensure that the desired spike or envelope 
proteins are being expressed to adequate levels in transfected cells and, more importantly, are 
efficiently incorporated into the budding pseudoparticles. This could be done by monitoring 
protein expression by using protein tags in plasmids carrying proteins of interest such as 
polyarginine (Arg), polyhistidine (His) or FLAG (a peptide consisting of aspartic acid, tyrosine 
and lysine residues) and analysing by western blot/immunofluorescence with the aid of specific 
antibodies (Terpe, 2003; Lau et al., 2018b). However, it is known that tagging of viral surface 
proteins can decrease their expression, localisation and could lead to conformational changes of 
the proteins of interest (Terpe, 2003; Waugh, 2005; Burg et al., 2016; Hoffmann, 2017; Saiz-
Baggetto et al., 2017; Booth et al., 2018), which has been known to influence the efficiency with 
which the S proteins are incorporated into pseudoparticles (Hoffmann, 2017). Therefore, tagging 
of S proteins was not performed in this study.  
NCK and Vero E6 cells were infected with pseudoparticles and fluorescence microscopy was 
used to detect GFP expressed by pseudopaticles once in cells. Other methods for determining 
the number of infected cells are available, such as antigen detection methods where fluorescent-
labelled antibodies recognise the virus of interest‟s surface protein in the cell, or monitoring of 
luciferase activity when infection had taken place (Beels et al., 2008; Hoffmann et al., 2013).  
After the NCK and Vero E6 infection experiments were analysed using fluorescence microscopy, 
it was found that the washing steps necessary to prepare the cells for fluorescence microscopy 
removed a large number of cells from slides, which could produce skewed results. Detection of 
GFP expression through flow cytometry was therefore regarded as the method of choice for this 
study, as less cells would be lost through washing. Furthermore, there was convenient access to 
a flow cytometry unit, sample processing was straightforward, and flow cytometry reduced the 
risk of errors compared to counting the total number of cells and the number of GFP expressing 
cells by eye when using fluorescence microscopy. In addition, the use of fluorescence 
microscopy introduces potential bias, since only certain fields on the slides are selected for 
counting while flow cytometry evaluates all cells in the sample. For one, the investigator might 
be tempted to select fields that represent results as hypothesised. Using flow cytometry 
therefore aids in determining the exact number of infected cells in the whole sample, unlike 
fluorescence microscopy, where some of the infected cells remain on the plate and only certain 
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fields on the slide are counted. The number of GFP expressing cells after infection of CaKi, 
NCK, NCL, NCT, PipNi, Vero E6 and Vero EMK cells were subsequently measured by flow 
cytometry.  
For infection of NCK cells, ppVSV-G had infected the highest number of cells; infection with 
ppEV showed the lowest number of infected cells, as was expected. Among infections with the 
pseudoparticles of interest, ppNCV-S elicited the highest number of infections, with ppMERS-S 
scoring second. As N. capensis bats are the natural hosts of NeoCoV, it was expected that 
ppNCV-S would elicit a high number of infections in NCK cells (Ithete et al., 2013; Corman et al., 
2014). The number of ppMERS-S-infected cells was considerably lower than that of ppNCV-S. 
Since the two viruses are 85.5% genetically identical, they would be expected to have the ability 
to infect the same host cells, though not necessarily with the same efficiency (Corman et al., 
2014). This difference could indicate that NeoCoV would have to undergo several genetic 
changes in its S protein before it could putatively infect humans (Ithete et al., 2013; Corman et 
al., 2014; Anthony et al., 2017). If such changes did indeed happen to a presumptive MERS-
CoV ancestral bat virus, resulting in MERS-CoV, the S proteins of the two viruses would differ in 
such a way as to make N. capensis cells less susceptible to MERS-CoV and human cells less 
susceptible to infection by NeoCoV (Anthony et al., 2017).  
The number of NCK cells infected by ppSARS-S, even though relatively high with ~4,60×104 
infections, were noticeably less than that infected by ppMERS-S and especially ppNCV-S, 
eliciting infection of only ~60% of the number of cells infected by ppNCV-S. This may be due to 
the fact that SARS-CoV is believed to have emerged in horseshoe bats and is less related to 
NeoCoV than MERS-CoV is, with their S1 and S2 subunits sharing only 20% and 42% similarity, 
respectively, consequently making it less probable that the SARS-CoV S protein is adapted to 
infect NeoCoV‟s original host (Corman et al., 2014). Nevertheless, a high level of infection was 
still observed, possibly due to the fact that the virus is adapted to infecting certain bat cells (Lau 
et al., 2005; Li et al., 2005).  
Infection of NCK cells resulted in the highest infection level by ppNCV-S across all the tested cell 
lines. Kidney cells are oftentimes the tissue in which coronaviruses replicate (de Haan & Rottier, 
2005; Mossel et al., 2005; Cavanagh et al., 2007; Pacciarini et al., 2008; Mackay & Arden, 
2015). With N. capensis bats being the natural host of NeoCoV (Ithete, 2013; Ithete et al., 2013; 
Corman et al., 2014), it was hypothesised that NeoCoV would have the ability to infect and 
replicate in NCK cells, as discussed in section 4.2. However, this hypothesis remains to be 
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confirmed as there is no evidence in the literature of N. capensis kidney samples testing positive 
for NeoCoV.  
The number of PipNi cells that were infected with each pseudotype is much smaller compared to 
the number of infected cells seen in NCK, Vero E6 and Vero EMK cells. MERS-related 
coronaviruses have been found in P. hesperidus bats (Cronjé, 2017), hence it is possible that 
these coronaviruses are not adapted to infect cells that originate from Pipistrellus species as 
efficiently as seen for N. capensis cells, but rather infect and replicate in other organs of 
Pipistrellus bats. However, MERS-related coronaviruses originating from Pipistrellus bats are 
closely related to NeoCoV and differ mainly in their S proteins (Cronjé, 2017). There is therefore 
a possibility that the MERS-CoV-related viruses detected in Pipistrellus bats are better adapted 
to their natural host and do replicate in the kidneys of their natural host, whereas NeoCoV is 
better adapted for binding and entering N. capensis cells.  
The large number of ppSARS-S-infected cells relative to the other pseudotypes of interest 
indicates that SARS-CoV is better adapted to infecting PipNi cells than MERS-CoV and 
NeoCoV. MERS-CoV has been found to infect PipNi cells (Müller et al., 2012; Raj et al., 2013), 
however the same was not reported for SARS-CoV. The findings of the current study indicate 
that SARS-CoV is able to bind to and enter PipNi cells; thus failure to culture SARS-CoV on 
PipNi cells is not due to its inability to enter the cells, but rather an inability to replicate in the 
cultures.  
The number of infections elicited with ppSARS-S infection was higher than the number of 
ppVSV-G-infected cells when infecting PipNi cells. This discrepancy could be the result of 
events measured by the flow cytometer that were not necessarily cells expressing GFP, such as 
the fluorescence of cell debris in the sample (Reardon et al., 2014). With the pseudoparticle 
infection of PipNi resulting in such low levels of infection, the proportion of autofluorescence in 
relation to the total fluorescence detected after PipNi infection is higher than the ratio of 
autofluorescence to GFP expressing cells for NCK, Vero E6 and Vero EMK cell infections, and 
therefore can be distinguished more prominently when analysing the results of PipNi infection. 
The number of cells expressing GFP after infection with ppEV was, nonetheless, lower than that 
for any of the other infections. It is therefore improbable that the high level of infection for 
ppSARS-S is only the result of fluorescence of cell debris.  
Infection of Vero E6 cells yielded similar results when infecting with the pseudoparticles of 
interest, with ppVSV-G having infected slightly more cells than the coronavirus pseudoparticles, 
and ppEV eliciting a very small proportion of infections. It is known that Vero E6 cells have the 
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receptor DPP4 for MERS-CoV (Raj et al., 2013) and the receptor ACE2 for SARS-CoV (Li et al., 
2003), therefore it was not unexpected that ppNCV-S is able to infect the same cell line, since 
NeoCoV and MERS-CoV share 87% similarity in their S2 subunits on an amino acid level. It 
might be reasoned that NeoCoV utilises either DPP4 or ACE2, or, if not one of these, another 
receptor that is present on Vero E6 cells, since the pseudotype bearing NeoCoV‟s surface 
antigen is able to infect Vero E6 cells to approximately the same level as viruses known to have 
the ability to infect Vero E6 cells. Furthermore, these results indicate that NeoCoV might be 
effectively transmitted from bats to non-human primates, where it might undergo modifications in 
its genome and recombine with other primate coronaviruses and increase its zoonotic potential 
and transmissibility (Corman et al., 2014).  
Lower numbers of infected cells were seen for the pseudotyped viruses of interest when 
infecting Vero EMK cells than were seen in the infection of Vero E6 cells. This is an 
unanticipated result, since the cell lines were derived from the same species. However, for 
infection with ppVSV-G, ~6% more Vero EMK than Vero E6 cells were successfully infected; 
ppEV infection of Vero EMK cells yielded a number of infected cells ~90% that of Vero E6 
infected cells with the pseudotype. As the infection levels of the controls among the two Vero 
cell lines are quite similar, the lower numbers of infected cells observed when infecting Vero 
EMK cells with the coronavirus pseudotypes could be the result of adaptations the two cell lines 
underwent once the strains of the cells were established. Since the VSV-G receptor, a low-
density lipoprotein, is conserved among several species and is present in most cell lines 
(Finkelshtein et al., 2013), cell culture adaptations might not have influenced the expression of 
this protein as it possibly did that of DPP4, ACE2 and the NeoCoV receptor in Vero EMK cells.  
Another interesting result is that the number of cells infected by ppNCV-S and ppSARS-S are 
very similar for infection of Vero EMK cells, while ppMERS-S has a much lower number of 
infected cells. Since the NeoCoV and MERS-CoV S proteins are more closely related than that 
of NeoCoV and SARS-CoV, it would be expected that ppMERS-S and ppNCV-S should elicit 
similar levels of infection. This could indicate that MERS-CoV has a narrower tropism than 
NeoCoV, leading to a lowered ability to infect the same cell lines as NeoCoV.  
Very low numbers of infected cells (<10 per pseudotype) were seen when infecting CaKi, NCL 
and NCT cells with all the pseudoparticles. Considering the autofluorescence of cell debris when 
measuring GFP expression with flow cytometry, it is very likely that these minimal numbers of 
GFP expressing cells were in fact autofluorescence and not the presence of infected cells 
(Reardon et al., 2014). Considering that no cells expressed GFP when infecting CaKi, NCL and 
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NCT cells, it can be hypothesised that CaKi, NCL and NCT cells do not express DDP4 and 
ACE2 receptors, nor the receptor for NeoCoV, which is yet unknown, for infection by MERS-
CoV, SARS-CoV and NeoCoV, respectively.  
Since NeoCoV and other MERS-related betacoronaviruses have been found in N. capensis bats 
(Ithete, 2013; Cronjé, 2017), the viruses‟ abilities to infect N. capensis cells are confirmed. 
Coronaviruses are often found in kidneys (de Haan & Rottier, 2005; Mossel et al., 2005; 
Cavanagh et al., 2007; Pacciarini et al., 2008; Mackay & Arden, 2015). Since the results of this 
study indicate that the three coronaviruses of interest are able to enter NCK cells, it can be 
hypothesised that these viruses use N. capensis kidneys as a site of replication and therefore do 
not utilise the lungs or trachea of N. capensis.  
Interestingly, CaKi cells were not susceptible to any of the pseudoparticles. MERS-CoV and 
antibodies for the virus have been detected in C. dromedarius individuals in the Middle East 
(Hilgenfeld & Peiris, 2013; Perera et al., 2013, Reusken et al., 2013; Adney et al., 2014; 
Coleman & Frieman, 2014; Haagmans et al., 2014; Nowotny & Kolodziejek, 2014), therefore it is 
expected that ppMERS-S should be able to infect CaKi cells and express GFP. However, 
MERS-CoV has not been reported to have been detected in C. dromedarius kidney tissue, nor 
has it been used to infect CaKi cells specifically; it is therefore not known whether the virus is 
able to infect the kidney cells themselves or if they infect other organ(s). If this is the case, the C. 
dromedarius kidney cells may not necessarily express the MERS-CoV receptor and the MERS-
CoV that has been discovered in C. dromedarius individuals did not originate from the kidneys.  
Since infection with pseudoparticles did not yield any GFP expression for ppNCV-S or ppSARS-
S, it can be hypothesised that CaKi cells do not express the receptors for NeoCoV or SARS-CoV 
either. It is, however, possible that the presence of Mycoplasma contamination in the CaKi cell 
cultures could have influenced the susceptibility of the cell line to the pseudoparticles. 
Mycoplasma contamination has been found to influence cell susceptibility to viral infection 
(Rottem & Barile, 1993) and can cause constant interferon signalling (Rinaldo et al., 1973), 
which would hinder infection. Unfortunately, no Mycoplasma-free CaKi cells were available for 
repeating the experiments to ensure that the results were reliable. It was not possible to cure the 
CaKi cells of Mycoplasma contamination in a timely manner that would have allowed for the use 
of cured cells that can be infected with viable pseudoparticles, since the use of a method such 
as antibiotic treatment, which is the most widely-used method available, is time-consuming. It 
could take up to two weeks to eradicate Mycoplasma contamination when using an appropriate 
antibiotic (Uphoff et al., 2012), by which time the pseudoparticles would have lost their viability. 
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Furthermore, antibiotic treatment introduces a variable in the experiment and it would be difficult 
to determine whether introducing a new antibiotic in the cell culture has an effect on the cells‟ 
metabolism (Kuhlmann, 1995). For future studies, infection with pseudoparticles with a known 
titre needs to be repeated using Mycoplasma-free CaKi cells in order to determine whether 
Mycoplasma contamination influenced the susceptibility of the cells in this study. To achieve this, 
fresh, uncontaminated aliquots of CaKi cells either need to be obtained from the source, or cells 
need to be cured using antibiotics, or other methods such as treating cells with ether-chloroform, 
heat-treatment, microfilter filtration or addition of macrophages to the culture (Uphoff & Drexler, 
2002b), followed by procedures to confirm that the cells are Mycoplasma-free and subsequently 
culturing the cured cells without the treatments for an extended period of time to ensure that the 
metabolism of the cells has returned to its natural state.  
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CHAPTER 5 
5  Conclusions 
Investigating potentially zoonotic coronaviruses that could lead to the emergence of important 
human pathogens is essential for the prevention or early detection of outbreaks. The current 
study has provided more information on the host range of one such virus, namely NeoCoV, 
through the use of viral pseudoparticles and attempts at isolating the virus in culture.  
Isolation of NeoCoV from bat faecal material was not achieved, even when using a cell line 
derived from the bat species N. capensis in which the virus was discovered. Different 
approaches need to be tested in order to find a protocol for the isolation of NeoCoV in cell 
culture. Future attempts at isolation could include the use of a fresh NeoCoV-positive sample, 
using higher titres of NeoCoV in inocula, agitated adsorption, and the use of transgenic cell lines 
expressing bat cell receptors and/or lacking interferon responses in order to circumvent the 
issue of innate bat immune mechanisms in cell culture. Furthermore, determining the NeoCoV 
receptor will greatly improve the probability of isolating the virus in cell culture.  
Infecting different cell lines with pseudoparticles revealed that a pseudotype carrying the S 
protein of NeoCoV was able to infect the kidney cells of N. capensis bats, in which NeoCoV was 
originally detected (Ithete, 2013; Ithete et al. 2013; Corman et al., 2014). The pseudotype 
carrying the S protein of NeoCoV also infected a high number of Vero E6 cells, similar to that of 
the pseudotype carrying the MERS-CoV S protein. This result leads to the assumption that 
NeoCoV would be able to infect the non-human primate C. aethiops, from which the Vero E6 cell 
line was derived. Taking this into account, it is possible that certain primate species, among 
others, might be links in the host „jumping‟ which is hypothesised to take place to allow zoonotic 
transmission of NeoCoV/MERS-CoV. This finding suggests that non-human primates might 
provide a suitable environment for the development of NeoCoV as a zoonotic agent. However, 
this needs to be further investigated by testing the NeoCoV S-bearing pseudoparticles on other 
non-human primate cell lines, as well as human cell lines such as HEK-293.  
It is unlikely that P. pipistrellus bats are a natural host for NeoCoV, since none of the 
pseudoparticles of interest infected PipNi cells at levels as high as seen in the infection of NCK, 
Vero E6 and Vero EMK cells. This theory should be further investigated by testing the 
pseudoparticles on cell lines originating from different P. pipistrellus organs, as the viruses might 
be able to infect other organs and possibly replicate in them. Furthermore, the transmissibility of 
MERS-CoV-related viruses detected in P. hesperidus bats can be tested by constructing 
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pseudoparticles bearing the S proteins of these viruses and using it to determine whether these 
viruses could infect N. capensis and P. pipistrellus cells.  
The lack of infections seen when inoculating the CaKi cells is surprising since it is expected that 
MERS-CoV should be able to infect dromedary camel kidney cells. The Mycoplasma infection of 
the CaKi cells could be the reason for seeing no infections in these cells. In future studies, 
pseudoparticles should be tested on CaKi cells that are Mycoplasma-free in order to determine 
whether the results observed for this cell line in the current study are reliable. As there is a 
possibility that the virus does not replicate in the kidney cells of C. dromedarius, the 
pseudoparticles also need to be tested on other cell lines originating from C. dromedarius, such 
as lung, trachea and pharynx cells for more conclusive findings.  
To better understand the possible emergence of NeoCoV, together with phylogenetic analyses, 
pseudoparticles could be used to infect cell lines that were not investigated in this study. Cell 
lines originating from domesticated animals and animals living in close proximity with humans, 
such as sheep, cattle, pigs, cats, dogs and rodents should also be tested. Testing the 
pseudoparticles on human cell lines from different organs will also provide insight into the ability 
of NeoCoV to infect humans directly. Doing so will ultimately lead to improved comprehension of 
the often complex events giving rise to the zoonotic transmission of coronaviruses.  
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ADDENDUM A 
Ethical clearance 
 
 
 
Protocol Approval 
Date: 15-Jun-2016 
PI Name: Ithete, Ndapewa L 
Protocol #: SU-ACUD16-00008 
Title: Investigation of novel bat-borne viruses with zoonotic potential in South Africa 
Dear Ndapewa Ithete, the Notiﬁcation, was reviewed on 06-Jun-2016 by the Research Ethics Committee: 
Animal Care and Use via committee review procedures and was approved. Please note that this 
clearance is only valid for a period of twelve months. Ethics clearance of protocols spanning more than 
one year must be renewed annually through submission of a progress report, up to a maximum of three 
years. 
Applicants are reminded that they are expected to comply with accepted standards for the use of 
animals in research and teaching as reﬂected in the South African National Standards 10386: 2008. 
The SANS 10386: 2008 document is available on the Division for Research Developments website 
www.sun.ac.za/research. 
As provided for in the Veterinary and Para-Veterinary Professions Act, 1982. It is the principal 
investigator's responsibility to ensure that all study participants are registered with or have been 
authorised by the South African Veterinary Council (SAVC) to perform the procedures on animals, or will 
be performing the procedures under the direct and continuous supervision of a SAVC-registered 
veterinary professional or SAVC-registered para-veterinary professional, who are acting within the scope 
of practice for their profession. 
Please remember to use your protocol number, SU-ACUD16-00008 on any documents or 
correspondence with the REC: ACU concerning your research protocol. 
Please note that the REC: ACU has the prerogative and authority to ask further questions, seek additional 
information, require further modiﬁcations or monitor the conduct of your research. 
Any event not consistent with routine expected outcomes that results in any unexpected animal welfare 
issue (death, disease, or prolonged distress) or human health risks (zoonotic disease or exposure, 
injuries) must be reported to the committee, by creating an Adverse Event submission within the system. 
We wish you the best as you conduct your research. 
If you have any questions or need further help, please contact the REC: ACU secretariat at or .  
Sincerely, 
REC: ACU Secretariat 
Research Ethics Committee: Animal Care and Us 
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ADDENDUM B 
Consumables, equipment and software 
Table B.1. List of consumables, equipment and software used in the current study.  
Consumables 
Consumable Catalogue number Company Country 
1.5 ml microcentrifuge 
tube 
0030 125.150 Eppendorf Germany 
2.0 ml microcentrifuge 
tube 
0030 120.094 Eppendorf Germany 
2.4 mm RNase & 
DNase free metal beads 
10032-370 Omni International USA 
10 μl low binding barrier 
pipette tips 
89136-155 Corning Incorporated USA 
100 μl low binding 
barrier pipette tips 
89136-159 Corning Incorporated USA 
1000 μl low binding 
barrier pipette tips 
89136-165 Corning Incorporated USA 
0.2 ml PCR 8-strip tubes 404001 
Nest Biotechnology Co., 
Ltd 
China 
15 ml centrifuge tubes 601002 
Nest Biotechnology Co., 
Ltd 
China 
50 ml centrifuge tubes 602002 
Nest Biotechnology Co., 
Ltd 
China 
100×15 mm Petri 
Dishes 
753001 
Nest Biotechnology Co., 
Ltd 
China 
Qubit assay tubes Q32856 Thermo Fisher Scientific USA 
Hard-shell PCR plates HSP9601 
Bio-Rad Laboratories, 
Inc.  
USA 
25 cm² cell culture 
flasks 
707003 
Nest Biotechnology Co., 
Ltd 
China 
75 cm² cell culture 
flasks 
708003 
Nest Biotechnology Co., 
Ltd 
China 
175 cm² cell culture 
flasks 
709003 
Nest Biotechnology Co., 
Ltd 
China 
6-well cell culture plates 703001 
Nest Biotechnology Co., 
Ltd 
China 
12-well cell culture 
plates 
712001 
Nest Biotechnology Co., 
Ltd 
China 
1 ml serological pipettes 324001 
Nest Biotechnology Co., 
Ltd 
China 
2 ml serological pipettes 325001 
Nest Biotechnology Co., 
Ltd 
China 
5 ml serological pipettes 326001 
Nest Biotechnology Co., 
Ltd 
China 
10 ml serological 
pipettes 
327001 
Nest Biotechnology Co., 
Ltd 
China 
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25 ml serological 
pipettes 
328001 
Nest Biotechnology Co., 
Ltd 
China 
50 ml serological 
pipettes 
329001 
Nest Biotechnology Co., 
Ltd 
China 
0.2 µm filter CLS431218 Corning Incorporated USA 
2.0 ml cryogenic vials 607001 
Nest Biotechnology Co., 
Ltd 
China 
Labstar Frosted 
Microscope Slides 
1000F-02-1009 Lasec SA South Africa 
16 mm Microscope 
Coverslips, round 
0111560 
Paul Marienfeld GmbH 
& Co. KG 
Germany 
5.0 ml polystyrene 
round-bottomed tube 
352054 Corning Incorporated USA 
BD CS&T Beads 656505 BD Biosciences USA 
Equipment 
Equipment Catalogue number Company Country 
D380 fridge D380 Defy Appliances South Africa 
EvoSafe Model VF360-
86 Ultra Low 
Temperature Upright 
Freezer 
VF360-86 Snijders Labs The Netherlands 
BioFlow II biological 
safety cabinet 
N/A Labotec South Africa 
10 μl pipette 3124000016 Eppendorf Germany 
100 μl pipette 3124000075 Eppendorf Germany 
1000 μl pipette 3124000121 Eppendorf Germany 
TissueLyser LT 69980 Qiagen Germany 
Prism microcentrifuge C2500 
Labnet International, 
Inc. 
USA 
AccuBlock digital dry 
bath 
D1200 
Labnet International, 
Inc. 
USA 
GeneAmp PCR System 
9700 
A24811 Thermo Fisher Scientific USA 
ENDURO Gel XL 
Electrophoresis System 
E0160 
Labnet International, 
Inc. 
USA 
UVITec Gel 
Documentation System 
1541 3202 1 Progen Scientific UK 
NanoDrop ND-1000 
Spectrophotometer V3.1 
N/A 
NanoDrop 
Technologies, Inc. 
USA 
Mr. Frosty Freezing 
Container 
5100-0001 Thermo Fisher Scientific USA 
Vortex mixer S0200 
Labnet International, 
Inc. 
USA 
Shaking Incubator 
Model 3081U 
3081U Labcon USA 
Megafuge 2.0R 75003085 Heraeus Germany 
Qubit 2.0 Fluorometer Q32866 Thermo Fisher Scientific USA 
CFX Connect Real-Time 185-5200 Bio-Rad Laboratories, USA 
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PCR Detection System Inc.  
MPS 1000 Mini Plate 
Spinner Centrifuge 
C1000 
Labnet International, 
Inc. 
USA 
US Autoflow Automatic 
CO2 Incubator 
N/A NuAire, Inc. USA 
FastPette Pro Pipette 
Controller 
P2002 
Labnet International, 
Inc. 
USA 
Primovert Inverted 
Microscope 
12-070-466 Carl Zeiss AG Germany 
Haemocytometer N/A N/A N/A 
ProBlot 25 Rocker 470126-522 
Labnet International, 
Inc. 
USA 
BD FACSCanto II flow 
cytometer 
640806 BD Biosciences USA 
Eclipse Ci microscope N/A Nikon Japan 
Software 
Software Company Country 
UVIproChemi software Progen Scientific UK 
ND-1000 V3.1.0 software NanoDrop Technologies, Inc. USA 
Geneious R10 bioinformatics 
software 
Biomatters Ltd. New Zealand 
CFX Manager Software Bio-Rad Laboratories, Inc.  USA 
ZEN software Carl Zeiss AG Germany 
FlowJo version 10.4.2 FlowJo, LLC USA 
Sperm Class Analyzer software MICROPTIC S.L. Spain 
BD FACSDiva software BD Biosciences USA 
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ADDENDUM C 
Sample information 
Table C.1. Bat faecal sample information.  
Sample number Sample name Bat species collected from Date of collection 
1 DC338 Neoromicia capensis 05/02/2017 
2 DC339 Neoromicia capensis 06/02/2017 
3 DC340 Neoromicia capensis 06/02/2017 
4 DC341 Neoromicia capensis 06/02/2017 
5 DC343 Pipistrellus hesperidus 06/02/2017 
6 DC345 Neoromicia capensis 06/02/2017 
7 DC346 Neoromicia capensis 06/02/2017 
8 DC364 Myotis tricolor 08/02/2017 
9 DC365 Myotis tricolor 08/02/2017 
10 DC366 Rhinolophus clivosus 08/02/2017 
11 DC367 Rhinolophus clivosus 08/02/2017 
12 DC370 Rhinolophus clivosus 08/02/2017 
13 DC373 Rhinolophus clivosus 08/02/2017 
14 DC378 Miniopterus natalensis 08/02/2017 
15 DC392 Pipistrellus hesperidus 08/02/2017 
16 DC422 Neoromicia capensis 12/02/2017 
17 DC427 Neoromicia capensis 12/02/2017 
18 DC431 Neoromicia capensis 12/02/2017 
19 DC432 Neoromicia capensis 12/02/2017 
20 DC433 Neoromicia capensis 12/02/2017 
21 DC435 Neoromicia capensis 13/02/2017 
22 DC445 Rhinolophus capensis 13/02/2017 
23 DC467 Neoromicia capensis 15/02/2017 
24 DC626 Pipistrellus hesperidus 06/05/2017 
25 DC627 Myotis bocagii 09/05/2017 
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26 DC629 Pipistrellus hesperidus 09/05/2017 
27 DC632 Pipistrellus hesperidus 09/05/2017 
28 DC633 Pipistrellus hesperidus 09/05/2017 
29 DC634 Pipistrellus hesperidus 09/05/2017 
30 DC638 Pipistrellus hesperidus 10/05/2017 
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ADDENDUM D 
Cell culture images 
 
Figure D.1. Cultures of the cell lines used in this study. Culture images were captured at 40ˣ 
magnification. Bar = 100 µm.  
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ADDENDUM E 
Flow cytometry graphs 
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Figure E.1. GFP expression measured through flow cytometry. A) Expression in infected CaKi cells. 
B) Expression in infected NCL cells. C) Expression in infected NCT cells. D) Expression in infected PipNi 
cells. E) Expression in infected Vero E6 cells. F) Expression in infected Vero EMK cells. Each graph 
shows the GFP measured per pseudoparticle, which was done in triplicate, therefore yielding three graphs 
per pseudoparticle. The first peak for each sample shows the cells that do not express GFP, with the 
smaller peaks (if present) showing the number of GFP expressing cells. The number of events is indicated 
on the y-axis, while the GFP fluorescence intensity is indicated on the x-axis.  
Stellenbosch University  https://scholar.sun.ac.za
